This regulatory network was inferred from the input dataset. The miRNAs and mRNAs are
presented as round and rectangle nodes respectively. The numerical value popped up upon mouse over the gene node is the log2 transformed fold-change of the gene expression between the two groups. All of the nodes are clickable, and the detailed information of the miRNAs/mRNAs and related cancer pathway will be displayed in another window. The edges between nodes are supported by both interactions (predicted or experimentally verified) and correlations learnt from cancer dataset. The numerical value popped up upon mouse over the edge is the correlation beat value (effect size) between the two nodes. The experimental evidences of the edges reported in previous cancer studies are highlighted by red/orange color. All of these information can be accessed by the "mouse-over" action. This network shows a full map of the miRNA-mRNA regulation of the input gene list(s), and the hub miRNAs (with the high network degree/betweenness centrality) would be the potential cancer drivers or tumor suppressors. The full result table can be accessed in the "Regulations" tab.
"miRNACancerMAP" is also a network visualization tool for users to draw their regulatory network by personal customization. Users can set the complexity of the network by limiting the number of nodes or edges. And the color of the nodes can be defined by different categories of the mRNAs and miRNAs, such as Gene-Ontology, pathway, and expression status. Users can also select to use network degree or network betweenness centrality to define the node size. And edges can be black or colored by the correlation. Purple edge means negative correlation (mostly found between miRNA and mRNA), and blue edge means positive correlation (found in PPI or miRNA-miRNA sponge effect). We can also add the protein-protein interactions (PPI) into the network. This result will show the cluster of genes regulated by some specific miRNAs. Additionally, miRNA-miRNA edges can be added by the "miRNA sponge" button, presenting some clusters of miRNAs that have the interactions via sponge effect.
Num | microRNA | Gene | miRNA log2FC | miRNA pvalue | Gene log2FC | Gene pvalue | Interaction | Correlation beta | Correlation P-value | PMID | Reported in cancer studies |
---|---|---|---|---|---|---|---|---|---|---|---|
1 | hsa-miR-106b-5p | APC | -0.3 | 0.86929 | 0.2 | 0.85295 | miRNAWalker2 validate; miRTarBase | -0.22 | 0 | 23087084 | miR 106b downregulates adenomatous polyposis coli and promotes cell proliferation in human hepatocellular carcinoma; Moreover we demonstrated that miR-106b downregulates APC expression by directly targeting the 3'-untranslated region of APC messenger RNA; Taken together our results suggest that miR-106b plays an important role in promoting the proliferation of human hepatoma cells and presents a novel mechanism of micro RNA-mediated direct suppression of APC expression in cancer cells |
2 | hsa-miR-148a-3p | APC | -0.1 | 0.97698 | 0.2 | 0.85295 | miRNAWalker2 validate | -0.12 | 0.00641 | NA | |
3 | hsa-miR-154-3p | APC | -0.17 | 0.5465 | 0.2 | 0.85295 | TargetScan | -0.12 | 0.00356 | NA | |
4 | hsa-miR-192-5p | APC | -0.12 | 0.97293 | 0.2 | 0.85295 | miRNAWalker2 validate | -0.11 | 0.00054 | NA | |
5 | hsa-miR-193a-3p | APC | -0.25 | 0.65436 | 0.2 | 0.85295 | miRanda | -0.15 | 0.00011 | NA | |
6 | hsa-miR-27a-3p | APC | -0.12 | 0.9588 | 0.2 | 0.85295 | miRNAWalker2 validate; miRTarBase; miRNATAP | -0.17 | 0.00984 | 22018270 | Finally the APC gene was identified as the direct and functional target of miR-27 |
7 | hsa-miR-335-3p | APC | -0.24 | 0.8845 | 0.2 | 0.85295 | mirMAP | -0.21 | 0 | NA | |
8 | hsa-miR-374a-5p | APC | -0.34 | 0.76692 | 0.2 | 0.85295 | mirMAP | -0.28 | 0 | NA | |
9 | hsa-miR-374b-5p | APC | -0.29 | 0.8357 | 0.2 | 0.85295 | mirMAP | -0.2 | 0.00044 | NA | |
10 | hsa-miR-421 | APC | -0.18 | 0.7347 | 0.2 | 0.85295 | miRanda | -0.15 | 0.0002 | NA | |
11 | hsa-miR-450b-5p | APC | -0.01 | 0.98315 | 0.2 | 0.85295 | miRNATAP | -0.17 | 6.0E-5 | NA | |
12 | hsa-miR-501-3p | APC | -0.75 | 0.55276 | 0.2 | 0.85295 | TargetScan | -0.12 | 0.00171 | NA | |
13 | hsa-miR-590-3p | APC | -0.28 | 0.59127 | 0.2 | 0.85295 | PITA; miRanda; mirMAP; miRNATAP | -0.1 | 0.00339 | NA | |
14 | hsa-miR-20a-3p | APC2 | 0.46 | 0.57674 | -0.38 | 0.36375 | mirMAP | -0.17 | 0.00956 | NA | |
15 | hsa-miR-452-3p | APC2 | -0.17 | 0.79901 | -0.38 | 0.36375 | mirMAP | -0.17 | 0.00953 | NA | |
16 | hsa-miR-582-5p | AXIN2 | -0.4 | 0.58123 | 0.16 | 0.92249 | miRNATAP | -0.54 | 0 | NA | |
17 | hsa-miR-195-3p | CACYBP | 0.12 | 0.69192 | 0.04 | 0.97693 | mirMAP | -0.15 | 0 | NA | |
18 | hsa-miR-30a-3p | CACYBP | 0.25 | 0.91709 | 0.04 | 0.97693 | MirTarget | -0.23 | 0 | NA | |
19 | hsa-miR-186-5p | CAMK2B | -0.32 | 0.85413 | 2.17 | 0.00982 | miRNAWalker2 validate; miRNATAP | -0.92 | 0 | NA | |
20 | hsa-miR-18a-5p | CAMK2B | -0.5 | 0.61264 | 2.17 | 0.00982 | mirMAP | -0.33 | 0.00078 | NA | |
21 | hsa-miR-362-3p | CAMK2B | -0.72 | 0.03459 | 2.17 | 0.00982 | miRanda | -0.39 | 0.00026 | NA | |
22 | hsa-miR-362-5p | CAMK2B | -0.27 | 0.75202 | 2.17 | 0.00982 | miRNATAP | -0.43 | 3.0E-5 | NA | |
23 | hsa-miR-577 | CAMK2B | -1.06 | 0.32606 | 2.17 | 0.00982 | miRNATAP | -0.33 | 0 | NA | |
24 | hsa-miR-589-3p | CAMK2B | -0.84 | 0.0112 | 2.17 | 0.00982 | MirTarget | -0.47 | 0 | NA | |
25 | hsa-miR-590-3p | CAMK2B | -0.28 | 0.59127 | 2.17 | 0.00982 | miRanda | -0.42 | 0.00016 | NA | |
26 | hsa-miR-625-5p | CAMK2B | -0.69 | 0.21031 | 2.17 | 0.00982 | mirMAP | -0.4 | 3.0E-5 | NA | |
27 | hsa-miR-628-5p | CAMK2B | -0.51 | 0.35193 | 2.17 | 0.00982 | miRNATAP | -0.53 | 0.00189 | NA | |
28 | hsa-miR-940 | CAMK2B | -0.23 | 0.68006 | 2.17 | 0.00982 | PITA; miRNATAP | -0.25 | 0.0094 | NA | |
29 | hsa-miR-708-3p | CAMK2D | 0.14 | 0.89698 | -0.33 | 0.80466 | mirMAP | -0.14 | 0.00023 | NA | |
30 | hsa-miR-181a-5p | CAMK2G | 0.03 | 0.98933 | 0.21 | 0.86839 | miRNATAP | -0.1 | 0.00195 | NA | |
31 | hsa-miR-181b-5p | CAMK2G | 0.16 | 0.93018 | 0.21 | 0.86839 | miRNATAP | -0.1 | 0.00173 | NA | |
32 | hsa-miR-628-5p | CAMK2G | -0.51 | 0.35193 | 0.21 | 0.86839 | MirTarget; PITA; miRNATAP | -0.17 | 0 | NA | |
33 | hsa-miR-16-5p | CCND1 | 0.01 | 0.99448 | -0.25 | 0.89067 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.13 | 0.00823 | 23991964; 22922827; 18483394 | At the molecular level our results further revealed that cyclin D1 expression was negatively regulated by miR-16;CCND1 has been found to be a target of miR-15a and miR-16-1 through analysis of complementary sequences between microRNAs and CCND1 mRNA; Moreover the transcription of CCND1 is suppressed by miR-15a and miR-16-1 via direct binding to the CCND1 3'-untranslated region 3'-UTR;Truncation in CCND1 mRNA alters miR 16 1 regulation in mantle cell lymphoma; Furthermore we demonstrated that this truncation alters miR-16-1 binding sites and through the use of reporter constructs we were able to show that miR-16-1 regulates CCND1 mRNA expression; This study introduces the role of miR-16-1 in the regulation of CCND1 in MCL |
34 | hsa-miR-195-5p | CCND1 | 0.34 | 0.74962 | -0.25 | 0.89067 | miRNAWalker2 validate; miRTarBase; MirTarget; miRNATAP | -0.14 | 0.00272 | 21350001; 26631043; 25823925 | Raf-1 and Ccnd1 were identified as novel direct targets of miR-195 and miR-497 miR-195/497 expression levels in clinical specimens were found to be correlated inversely with malignancy of breast cancer;MiR 195 inhibits the proliferation of human cervical cancer cells by directly targeting cyclin D1; The present study was to evaluate the level of miR-195 and cyclin D1 in CC tissues and cells; We further investigated the molecular mechanisms of miR-195 and cyclin D1 in CC cell lines HeLa and SiHa; Furthermore the expression of miR-195 was inversely proportional to that of cyclin D1 mRNA or protein pā=ā0.013 pā=ā0.015 respectively; However the inhibitor of miR-195 promoted the expression of cyclin D1 and cell proliferation; In conclusion our data suggest that miR-195 may have the potential role in treatment of CC patients as well as miR-195 is a novel regulator of invasiveness and tumorigenicity in CC cells by targeting cyclin D1;MicroRNA profiling identifies MiR 195 suppresses osteosarcoma cell metastasis by targeting CCND1; Meanwhile CCND1 was identified as the target gene of miR-195 and further studied; More importantly using real-time PCR we evaluated the expression of miR-195 and CCND1 in osteosarcoma samples from 107 frozen biopsy tissues and 99 formalin- or paraformalin-fixed paraffin-embedded FFPE tissues; Results indicated lowly expressed miR-195 or highly CCND1 correlated with positive overall survival and their expression inversely related to each other; In summary our study suggests miR-195 functions as a tumor metastasis suppressor gene by down-regulating CCND1 and can be used as a potential target in the treatment of osteosarcoma |
35 | hsa-miR-29c-3p | CCND1 | 0.16 | 0.94272 | -0.25 | 0.89067 | mirMAP | -0.14 | 0.00181 | NA | |
36 | hsa-miR-24-3p | CHD8 | -0.05 | 0.98527 | -0.23 | 0.87207 | miRNAWalker2 validate | -0.17 | 0.00183 | NA | |
37 | hsa-miR-493-5p | CREBBP | 0.23 | 0.73198 | -0.07 | 0.96314 | miRNATAP | -0.13 | 0.00036 | NA | |
38 | hsa-miR-30e-5p | CSNK1A1 | -0.07 | 0.97968 | 0.04 | 0.98107 | MirTarget | -0.11 | 0.00277 | NA | |
39 | hsa-miR-146b-5p | CSNK2A2 | -0.4 | 0.83751 | 0.05 | 0.96212 | miRanda | -0.17 | 0 | NA | |
40 | hsa-miR-212-3p | CSNK2A2 | -0.02 | 0.97323 | 0.05 | 0.96212 | mirMAP | -0.12 | 0.00416 | NA | |
41 | hsa-miR-92b-3p | CSNK2A2 | -0.57 | 0.68932 | 0.05 | 0.96212 | mirMAP | -0.11 | 0.00058 | NA | |
42 | hsa-miR-140-5p | CTNNB1 | -0.23 | 0.84733 | -0.27 | 0.89738 | miRanda | -0.14 | 0.00185 | NA | |
43 | hsa-let-7f-1-3p | CXXC4 | -0.31 | 0.69341 | 0.79 | 0.21218 | mirMAP | -0.52 | 0.00404 | NA | |
44 | hsa-miR-126-5p | CXXC4 | 0.08 | 0.95664 | 0.79 | 0.21218 | MirTarget; mirMAP | -0.43 | 0.00513 | NA | |
45 | hsa-miR-146b-5p | CXXC4 | -0.4 | 0.83751 | 0.79 | 0.21218 | MirTarget; miRNATAP | -0.66 | 0 | NA | |
46 | hsa-miR-223-3p | CXXC4 | -0.45 | 0.80968 | 0.79 | 0.21218 | MirTarget | -0.33 | 9.0E-5 | NA | |
47 | hsa-miR-338-5p | CXXC4 | 0.48 | 0.39396 | 0.79 | 0.21218 | MirTarget; miRNATAP | -0.3 | 0.00058 | NA | |
48 | hsa-miR-576-5p | CXXC4 | -0.51 | 0.41719 | 0.79 | 0.21218 | mirMAP | -0.32 | 0.00846 | NA | |
49 | hsa-miR-582-5p | CXXC4 | -0.4 | 0.58123 | 0.79 | 0.21218 | MirTarget; miRNATAP | -0.4 | 0.00183 | NA | |
50 | hsa-miR-589-5p | CXXC4 | -0.45 | 0.72273 | 0.79 | 0.21218 | MirTarget; miRNATAP | -0.63 | 0.00012 | NA | |
51 | hsa-miR-7-1-3p | CXXC4 | -0.46 | 0.6659 | 0.79 | 0.21218 | mirMAP | -0.36 | 0.00207 | NA | |
52 | hsa-let-7a-3p | DAAM1 | -0.22 | 0.85543 | -0.17 | 0.85781 | MirTarget | -0.14 | 0.00396 | NA | |
53 | hsa-let-7g-3p | DAAM1 | -0.49 | 0.62942 | -0.17 | 0.85781 | MirTarget | -0.12 | 0.00136 | NA | |
54 | hsa-miR-125a-5p | DAAM1 | -0 | 0.99916 | -0.17 | 0.85781 | MirTarget | -0.15 | 0.00828 | NA | |
55 | hsa-miR-130a-3p | DAAM1 | 0.09 | 0.9291 | -0.17 | 0.85781 | MirTarget; miRNATAP | -0.19 | 5.0E-5 | NA | |
56 | hsa-miR-130b-3p | DAAM1 | -0.22 | 0.82466 | -0.17 | 0.85781 | MirTarget; miRNATAP | -0.19 | 3.0E-5 | NA | |
57 | hsa-miR-130b-5p | DAAM1 | -0.65 | 0.3791 | -0.17 | 0.85781 | MirTarget | -0.13 | 0.00225 | NA | |
58 | hsa-miR-140-5p | DAAM1 | -0.23 | 0.84733 | -0.17 | 0.85781 | miRanda | -0.2 | 0.00199 | NA | |
59 | hsa-miR-142-3p | DAAM1 | -0.15 | 0.9461 | -0.17 | 0.85781 | miRanda | -0.11 | 0.00177 | NA | |
60 | hsa-miR-186-5p | DAAM1 | -0.32 | 0.85413 | -0.17 | 0.85781 | MirTarget; mirMAP | -0.2 | 0.00143 | NA | |
61 | hsa-miR-19a-3p | DAAM1 | -0.21 | 0.84464 | -0.17 | 0.85781 | miRNATAP | -0.16 | 2.0E-5 | NA | |
62 | hsa-miR-19b-3p | DAAM1 | -0.03 | 0.98666 | -0.17 | 0.85781 | miRNATAP | -0.22 | 0 | NA | |
63 | hsa-miR-27a-3p | DAAM1 | -0.12 | 0.9588 | -0.17 | 0.85781 | miRNATAP | -0.32 | 0 | NA | |
64 | hsa-miR-29a-3p | DAAM1 | 0.01 | 0.99698 | -0.17 | 0.85781 | MirTarget; miRNATAP | -0.31 | 0 | NA | |
65 | hsa-miR-29b-3p | DAAM1 | -0.1 | 0.95899 | -0.17 | 0.85781 | MirTarget; miRNATAP | -0.21 | 0 | NA | |
66 | hsa-miR-32-3p | DAAM1 | -0.57 | 0.13133 | -0.17 | 0.85781 | mirMAP | -0.12 | 0.00012 | NA | |
67 | hsa-miR-32-5p | DAAM1 | -0.06 | 0.95298 | -0.17 | 0.85781 | miRNATAP | -0.14 | 0.00133 | NA | |
68 | hsa-miR-335-5p | DAAM1 | -0.03 | 0.97338 | -0.17 | 0.85781 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.16 | 9.0E-5 | NA | |
69 | hsa-miR-362-3p | DAAM1 | -0.72 | 0.03459 | -0.17 | 0.85781 | MirTarget; miRanda; miRNATAP | -0.16 | 1.0E-5 | NA | |
70 | hsa-miR-429 | DAAM1 | -0.46 | 0.80624 | -0.17 | 0.85781 | miRNATAP | -0.1 | 0.00409 | NA | |
71 | hsa-miR-452-5p | DAAM1 | -0.05 | 0.97387 | -0.17 | 0.85781 | MirTarget | -0.16 | 0.00025 | NA | |
72 | hsa-miR-454-3p | DAAM1 | -0.1 | 0.84355 | -0.17 | 0.85781 | MirTarget; miRNATAP | -0.17 | 0.00176 | NA | |
73 | hsa-miR-548o-3p | DAAM1 | -0.19 | 0.51773 | -0.17 | 0.85781 | mirMAP | -0.11 | 0.00528 | NA | |
74 | hsa-miR-590-3p | DAAM1 | -0.28 | 0.59127 | -0.17 | 0.85781 | MirTarget; miRanda; mirMAP | -0.13 | 0.00054 | NA | |
75 | hsa-miR-92a-3p | DAAM1 | 0.03 | 0.99325 | -0.17 | 0.85781 | miRNATAP | -0.19 | 2.0E-5 | NA | |
76 | hsa-miR-141-5p | DAAM2 | -0.35 | 0.86764 | 0.12 | 0.86624 | mirMAP | -0.6 | 0 | NA | |
77 | hsa-miR-182-5p | DAAM2 | -0.1 | 0.97338 | 0.12 | 0.86624 | mirMAP | -0.36 | 0 | NA | |
78 | hsa-miR-18a-5p | DAAM2 | -0.5 | 0.61264 | 0.12 | 0.86624 | miRNAWalker2 validate | -0.46 | 0 | NA | |
79 | hsa-miR-193a-3p | DAAM2 | -0.25 | 0.65436 | 0.12 | 0.86624 | miRanda | -0.34 | 2.0E-5 | NA | |
80 | hsa-miR-1976 | DAAM2 | -0.28 | 0.707 | 0.12 | 0.86624 | mirMAP | -0.53 | 0 | NA | |
81 | hsa-miR-19b-3p | DAAM2 | -0.03 | 0.98666 | 0.12 | 0.86624 | miRNAWalker2 validate | -0.59 | 0 | NA | |
82 | hsa-miR-335-5p | DAAM2 | -0.03 | 0.97338 | 0.12 | 0.86624 | mirMAP | -0.56 | 0 | NA | |
83 | hsa-miR-339-5p | DAAM2 | -0.3 | 0.71291 | 0.12 | 0.86624 | miRanda | -0.55 | 0 | NA | |
84 | hsa-miR-361-3p | DAAM2 | -0.29 | 0.84773 | 0.12 | 0.86624 | mirMAP | -0.33 | 0.00993 | NA | |
85 | hsa-miR-369-3p | DAAM2 | 0.12 | 0.8323 | 0.12 | 0.86624 | mirMAP | -0.27 | 0.00212 | NA | |
86 | hsa-miR-421 | DAAM2 | -0.18 | 0.7347 | 0.12 | 0.86624 | PITA; miRanda | -0.35 | 1.0E-5 | NA | |
87 | hsa-miR-429 | DAAM2 | -0.46 | 0.80624 | 0.12 | 0.86624 | miRNATAP | -0.55 | 0 | NA | |
88 | hsa-miR-589-3p | DAAM2 | -0.84 | 0.0112 | 0.12 | 0.86624 | mirMAP | -0.35 | 0 | NA | |
89 | hsa-miR-590-3p | DAAM2 | -0.28 | 0.59127 | 0.12 | 0.86624 | miRanda; mirMAP | -0.58 | 0 | NA | |
90 | hsa-miR-592 | DAAM2 | -0.18 | 0.85623 | 0.12 | 0.86624 | mirMAP | -0.12 | 0.00127 | NA | |
91 | hsa-miR-107 | DKK1 | -0.04 | 0.98836 | 2.12 | 0.01001 | miRanda | -1.07 | 0.00153 | NA | |
92 | hsa-miR-16-2-3p | DKK1 | -0.37 | 0.54685 | 2.12 | 0.01001 | mirMAP | -0.73 | 7.0E-5 | NA | |
93 | hsa-miR-590-3p | DKK1 | -0.28 | 0.59127 | 2.12 | 0.01001 | PITA; miRanda; mirMAP; miRNATAP | -0.61 | 0.00025 | NA | |
94 | hsa-miR-142-3p | DKK2 | -0.15 | 0.9461 | 0.67 | 0.21846 | miRanda | -0.29 | 0.00978 | NA | |
95 | hsa-miR-193a-3p | DKK2 | -0.25 | 0.65436 | 0.67 | 0.21846 | miRanda | -0.34 | 0.00831 | NA | |
96 | hsa-miR-221-3p | DKK2 | 0.09 | 0.95912 | 0.67 | 0.21846 | miRNAWalker2 validate; miRTarBase | -0.89 | 0 | NA | |
97 | hsa-miR-27a-3p | DKK2 | -0.12 | 0.9588 | 0.67 | 0.21846 | miRNATAP | -0.74 | 0.00065 | NA | |
98 | hsa-miR-324-5p | DKK2 | -0.5 | 0.53742 | 0.67 | 0.21846 | miRanda | -0.69 | 0 | NA | |
99 | hsa-miR-335-5p | DKK2 | -0.03 | 0.97338 | 0.67 | 0.21846 | miRNAWalker2 validate | -0.74 | 0 | NA | |
100 | hsa-miR-33a-3p | DKK2 | -0.79 | 0.01052 | 0.67 | 0.21846 | mirMAP | -0.52 | 1.0E-5 | NA | |
101 | hsa-miR-361-5p | DKK2 | -0.14 | 0.9415 | 0.67 | 0.21846 | miRanda | -0.99 | 1.0E-5 | NA | |
102 | hsa-miR-374a-5p | DKK2 | -0.34 | 0.76692 | 0.67 | 0.21846 | mirMAP | -0.61 | 0.00163 | NA | |
103 | hsa-miR-374b-5p | DKK2 | -0.29 | 0.8357 | 0.67 | 0.21846 | mirMAP | -0.9 | 0 | NA | |
104 | hsa-miR-486-5p | DKK2 | -0.55 | 0.6964 | 0.67 | 0.21846 | miRanda; miRNATAP | -0.39 | 1.0E-5 | NA | |
105 | hsa-miR-576-5p | DKK2 | -0.51 | 0.41719 | 0.67 | 0.21846 | mirMAP | -0.82 | 0 | NA | |
106 | hsa-miR-590-3p | DKK2 | -0.28 | 0.59127 | 0.67 | 0.21846 | miRanda; mirMAP; miRNATAP | -0.76 | 0 | NA | |
107 | hsa-miR-590-5p | DKK2 | -0.55 | 0.47274 | 0.67 | 0.21846 | miRanda | -0.77 | 0 | NA | |
108 | hsa-miR-221-3p | DVL2 | 0.09 | 0.95912 | -0.17 | 0.88279 | miRNAWalker2 validate | -0.11 | 0.0034 | 21487968 | MiR 221 expression affects invasion potential of human prostate carcinoma cell lines by targeting DVL2; We also suggest that miR-221 may control the migration of AIPC cells through DVL2 working as a key regulator in advanced CaP |
109 | hsa-miR-21-5p | DVL3 | -0.15 | 0.97024 | 0.02 | 0.98794 | mirMAP | -0.13 | 0.00029 | NA | |
110 | hsa-miR-106b-5p | EP300 | -0.3 | 0.86929 | -0.28 | 0.85828 | miRNATAP | -0.13 | 0.00096 | NA | |
111 | hsa-miR-26b-5p | EP300 | -0.02 | 0.99038 | -0.28 | 0.85828 | miRNAWalker2 validate; miRNATAP | -0.12 | 0.00816 | NA | |
112 | hsa-miR-339-5p | EP300 | -0.3 | 0.71291 | -0.28 | 0.85828 | miRanda | -0.11 | 0.00013 | NA | |
113 | hsa-miR-369-3p | EP300 | 0.12 | 0.8323 | -0.28 | 0.85828 | MirTarget; PITA; miRNATAP | -0.15 | 1.0E-5 | NA | |
114 | hsa-miR-374a-5p | FBXW11 | -0.34 | 0.76692 | 0.06 | 0.96203 | mirMAP | -0.12 | 0.00016 | NA | |
115 | hsa-miR-505-3p | FBXW11 | -0.47 | 0.69038 | 0.06 | 0.96203 | mirMAP | -0.1 | 0.00011 | NA | |
116 | hsa-miR-22-3p | FRAT2 | 0.06 | 0.98656 | -0.19 | 0.86974 | miRNAWalker2 validate; MirTarget; miRNATAP | -0.19 | 0.00288 | NA | |
117 | hsa-miR-1275 | FZD1 | -0.83 | 0.08038 | -0.05 | 0.95908 | MirTarget | -0.12 | 0.00038 | NA | |
118 | hsa-miR-146a-5p | FZD1 | -0.58 | 0.73685 | -0.05 | 0.95908 | MirTarget | -0.18 | 3.0E-5 | NA | |
119 | hsa-miR-148b-5p | FZD1 | -0.24 | 0.43926 | -0.05 | 0.95908 | MirTarget | -0.28 | 0 | NA | |
120 | hsa-miR-186-5p | FZD1 | -0.32 | 0.85413 | -0.05 | 0.95908 | mirMAP | -0.44 | 0 | NA | |
121 | hsa-miR-192-5p | FZD1 | -0.12 | 0.97293 | -0.05 | 0.95908 | miRNAWalker2 validate | -0.29 | 0 | NA | |
122 | hsa-miR-200a-5p | FZD1 | -0.67 | 0.78126 | -0.05 | 0.95908 | MirTarget | -0.28 | 0 | NA | |
123 | hsa-miR-200b-5p | FZD1 | -0.5 | 0.72226 | -0.05 | 0.95908 | MirTarget | -0.34 | 0 | NA | |
124 | hsa-miR-29a-3p | FZD1 | 0.01 | 0.99698 | -0.05 | 0.95908 | mirMAP | -0.41 | 0 | NA | |
125 | hsa-miR-29b-3p | FZD1 | -0.1 | 0.95899 | -0.05 | 0.95908 | mirMAP | -0.39 | 0 | NA | |
126 | hsa-miR-335-5p | FZD1 | -0.03 | 0.97338 | -0.05 | 0.95908 | miRNAWalker2 validate | -0.29 | 0 | NA | |
127 | hsa-miR-577 | FZD1 | -1.06 | 0.32606 | -0.05 | 0.95908 | MirTarget; PITA | -0.19 | 0 | NA | |
128 | hsa-miR-590-3p | FZD1 | -0.28 | 0.59127 | -0.05 | 0.95908 | miRanda | -0.29 | 0 | NA | |
129 | hsa-miR-93-3p | FZD1 | -0.44 | 0.5499 | -0.05 | 0.95908 | MirTarget | -0.33 | 0 | NA | |
130 | hsa-miR-140-3p | FZD10 | -0.37 | 0.86476 | 0.67 | 0.34352 | miRNATAP | -0.87 | 0.00824 | NA | |
131 | hsa-miR-15b-5p | FZD10 | -0.27 | 0.87097 | 0.67 | 0.34352 | miRNATAP | -0.76 | 0.00034 | NA | |
132 | hsa-miR-16-5p | FZD10 | 0.01 | 0.99448 | 0.67 | 0.34352 | miRNATAP | -0.66 | 0.00183 | NA | |
133 | hsa-miR-92b-3p | FZD10 | -0.57 | 0.68932 | 0.67 | 0.34352 | miRNATAP | -0.85 | 0 | NA | |
134 | hsa-miR-30a-3p | FZD3 | 0.25 | 0.91709 | -0.71 | 0.30817 | mirMAP | -0.5 | 0 | NA | |
135 | hsa-miR-30a-5p | FZD3 | 0.22 | 0.93395 | -0.71 | 0.30817 | MirTarget; miRNATAP | -0.73 | 0 | NA | |
136 | hsa-miR-30e-5p | FZD3 | -0.07 | 0.97968 | -0.71 | 0.30817 | MirTarget | -0.31 | 0.00776 | NA | |
137 | hsa-let-7a-3p | FZD4 | -0.22 | 0.85543 | 0.09 | 0.9264 | mirMAP | -0.24 | 2.0E-5 | NA | |
138 | hsa-let-7d-5p | FZD4 | -0.14 | 0.93416 | 0.09 | 0.9264 | MirTarget; miRNATAP | -0.38 | 1.0E-5 | NA | |
139 | hsa-let-7f-1-3p | FZD4 | -0.31 | 0.69341 | 0.09 | 0.9264 | mirMAP | -0.33 | 2.0E-5 | NA | |
140 | hsa-let-7f-5p | FZD4 | 0.05 | 0.98728 | 0.09 | 0.9264 | MirTarget; miRNATAP | -0.24 | 0.00274 | NA | |
141 | hsa-let-7g-3p | FZD4 | -0.49 | 0.62942 | 0.09 | 0.9264 | MirTarget; miRNATAP | -0.25 | 0 | NA | |
142 | hsa-let-7g-5p | FZD4 | -0.2 | 0.92299 | 0.09 | 0.9264 | MirTarget; miRNATAP | -0.45 | 0 | NA | |
143 | hsa-miR-106b-5p | FZD4 | -0.3 | 0.86929 | 0.09 | 0.9264 | miRNATAP | -0.46 | 0 | NA | |
144 | hsa-miR-107 | FZD4 | -0.04 | 0.98836 | 0.09 | 0.9264 | miRNATAP | -0.29 | 0.00077 | NA | |
145 | hsa-miR-10a-5p | FZD4 | 0.07 | 0.98377 | 0.09 | 0.9264 | MirTarget | -0.28 | 0 | NA | |
146 | hsa-miR-130b-3p | FZD4 | -0.22 | 0.82466 | 0.09 | 0.9264 | mirMAP | -0.41 | 0 | NA | |
147 | hsa-miR-141-3p | FZD4 | -0.32 | 0.87774 | 0.09 | 0.9264 | TargetScan | -0.35 | 0 | NA | |
148 | hsa-miR-15a-5p | FZD4 | -0.07 | 0.96484 | 0.09 | 0.9264 | MirTarget | -0.4 | 0 | NA | |
149 | hsa-miR-15b-5p | FZD4 | -0.27 | 0.87097 | 0.09 | 0.9264 | MirTarget | -0.32 | 0 | NA | |
150 | hsa-miR-16-5p | FZD4 | 0.01 | 0.99448 | 0.09 | 0.9264 | MirTarget | -0.39 | 0 | NA |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | WNT SIGNALING PATHWAY | 61 | 351 | 7.448e-87 | 3.466e-83 |
2 | CANONICAL WNT SIGNALING PATHWAY | 32 | 95 | 2.5e-53 | 5.817e-50 |
3 | REGULATION OF WNT SIGNALING PATHWAY | 38 | 310 | 2.92e-45 | 4.528e-42 |
4 | NON CANONICAL WNT SIGNALING PATHWAY | 31 | 140 | 4.233e-45 | 4.924e-42 |
5 | NEGATIVE REGULATION OF WNT SIGNALING PATHWAY | 31 | 197 | 4.281e-40 | 3.984e-37 |
6 | REGULATION OF ANATOMICAL STRUCTURE MORPHOGENESIS | 46 | 1021 | 1.634e-35 | 1.267e-32 |
7 | REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 28 | 236 | 1.637e-32 | 1.088e-29 |
8 | NEGATIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 25 | 162 | 5.603e-32 | 3.259e-29 |
9 | REGULATION OF MULTICELLULAR ORGANISMAL DEVELOPMENT | 50 | 1672 | 1.41e-30 | 7.292e-28 |
10 | REGULATION OF ORGAN MORPHOGENESIS | 26 | 242 | 5.324e-29 | 2.477e-26 |
11 | WNT SIGNALING PATHWAY CALCIUM MODULATING PATHWAY | 16 | 39 | 2.399e-28 | 1.015e-25 |
12 | NEGATIVE REGULATION OF CELL COMMUNICATION | 41 | 1192 | 1.351e-26 | 5.239e-24 |
13 | POSITIVE REGULATION OF RESPONSE TO STIMULUS | 48 | 1929 | 1.505e-25 | 5.388e-23 |
14 | NEGATIVE REGULATION OF RESPONSE TO STIMULUS | 42 | 1360 | 1.763e-25 | 5.861e-23 |
15 | REGULATION OF ESTABLISHMENT OF PLANAR POLARITY | 18 | 110 | 1.357e-23 | 4.21e-21 |
16 | POSITIVE REGULATION OF CELL COMMUNICATION | 42 | 1532 | 1.827e-23 | 5.314e-21 |
17 | EMBRYO DEVELOPMENT ENDING IN BIRTH OR EGG HATCHING | 29 | 554 | 2.262e-23 | 6.191e-21 |
18 | REGULATION OF CELL DIFFERENTIATION | 41 | 1492 | 7.178e-23 | 1.856e-20 |
19 | TISSUE DEVELOPMENT | 41 | 1518 | 1.376e-22 | 3.37e-20 |
20 | POSITIVE REGULATION OF GENE EXPRESSION | 43 | 1733 | 2.14e-22 | 4.979e-20 |
21 | EPITHELIUM DEVELOPMENT | 34 | 945 | 2.679e-22 | 5.936e-20 |
22 | POSITIVE REGULATION OF PROTEIN METABOLIC PROCESS | 40 | 1492 | 7.518e-22 | 1.59e-19 |
23 | REGULATION OF EMBRYONIC DEVELOPMENT | 17 | 114 | 1.357e-21 | 2.744e-19 |
24 | TUBE MORPHOGENESIS | 23 | 323 | 1.661e-21 | 3.221e-19 |
25 | TISSUE MORPHOGENESIS | 27 | 533 | 2.351e-21 | 4.376e-19 |
26 | TUBE DEVELOPMENT | 27 | 552 | 5.841e-21 | 1.045e-18 |
27 | MORPHOGENESIS OF AN EPITHELIUM | 24 | 400 | 1.11e-20 | 1.913e-18 |
28 | PATTERN SPECIFICATION PROCESS | 24 | 418 | 3.107e-20 | 5.163e-18 |
29 | EMBRYO DEVELOPMENT | 31 | 894 | 9.121e-20 | 1.463e-17 |
30 | POSITIVE REGULATION OF DEVELOPMENTAL PROCESS | 34 | 1142 | 1.058e-19 | 1.588e-17 |
31 | REGULATION OF PROTEIN MODIFICATION PROCESS | 40 | 1710 | 1.058e-19 | 1.588e-17 |
32 | ORGAN MORPHOGENESIS | 30 | 841 | 1.898e-19 | 2.76e-17 |
33 | CARDIOVASCULAR SYSTEM DEVELOPMENT | 29 | 788 | 3.801e-19 | 5.202e-17 |
34 | CIRCULATORY SYSTEM DEVELOPMENT | 29 | 788 | 3.801e-19 | 5.202e-17 |
35 | POSITIVE REGULATION OF BIOSYNTHETIC PROCESS | 40 | 1805 | 7.319e-19 | 9.66e-17 |
36 | NEUROGENESIS | 36 | 1402 | 7.681e-19 | 9.66e-17 |
37 | EMBRYONIC MORPHOGENESIS | 25 | 539 | 7.63e-19 | 9.66e-17 |
38 | BETA CATENIN DESTRUCTION COMPLEX DISASSEMBLY | 10 | 22 | 1.258e-18 | 1.5e-16 |
39 | POSITIVE REGULATION OF CELL DIFFERENTIATION | 29 | 823 | 1.231e-18 | 1.5e-16 |
40 | NEURON DIFFERENTIATION | 29 | 874 | 6.201e-18 | 7.213e-16 |
41 | REGIONALIZATION | 20 | 311 | 7.083e-18 | 8.039e-16 |
42 | REGULATION OF PHOSPHORUS METABOLIC PROCESS | 37 | 1618 | 9.645e-18 | 1.069e-15 |
43 | REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 37 | 1656 | 2.067e-17 | 2.237e-15 |
44 | INTRACELLULAR SIGNAL TRANSDUCTION | 36 | 1572 | 3.073e-17 | 3.25e-15 |
45 | POSITIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 34 | 1395 | 5.023e-17 | 5.193e-15 |
46 | NEGATIVE REGULATION OF DEVELOPMENTAL PROCESS | 27 | 801 | 7.608e-17 | 7.696e-15 |
47 | POSITIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 31 | 1135 | 8.098e-17 | 8.017e-15 |
48 | HEART DEVELOPMENT | 22 | 466 | 9.125e-17 | 8.845e-15 |
49 | NEURAL TUBE DEVELOPMENT | 15 | 149 | 1.673e-16 | 1.588e-14 |
50 | CELL FATE COMMITMENT | 17 | 227 | 2.115e-16 | 1.968e-14 |
51 | REGULATION OF CELLULAR PROTEIN LOCALIZATION | 23 | 552 | 2.478e-16 | 2.261e-14 |
52 | POSITIVE REGULATION OF MOLECULAR FUNCTION | 37 | 1791 | 2.65e-16 | 2.371e-14 |
53 | POSITIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 29 | 1036 | 5.613e-16 | 4.837e-14 |
54 | POSITIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 29 | 1036 | 5.613e-16 | 4.837e-14 |
55 | REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 19 | 337 | 5.914e-16 | 5.003e-14 |
56 | ANATOMICAL STRUCTURE FORMATION INVOLVED IN MORPHOGENESIS | 28 | 957 | 6.68e-16 | 5.55e-14 |
57 | MORPHOGENESIS OF EMBRYONIC EPITHELIUM | 14 | 134 | 1.077e-15 | 8.79e-14 |
58 | REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 36 | 1784 | 1.674e-15 | 1.343e-13 |
59 | REGULATION OF CELLULAR RESPONSE TO STRESS | 24 | 691 | 2.904e-15 | 2.29e-13 |
60 | CELLULAR RESPONSE TO ORGANIC SUBSTANCE | 36 | 1848 | 5.017e-15 | 3.891e-13 |
61 | SEGMENTATION | 12 | 89 | 5.776e-15 | 4.406e-13 |
62 | ANTERIOR POSTERIOR PATTERN SPECIFICATION | 15 | 194 | 8.887e-15 | 6.669e-13 |
63 | NEURAL TUBE FORMATION | 12 | 94 | 1.141e-14 | 8.429e-13 |
64 | DORSAL VENTRAL AXIS SPECIFICATION | 8 | 20 | 1.474e-14 | 1.072e-12 |
65 | TUBE FORMATION | 13 | 129 | 1.947e-14 | 1.394e-12 |
66 | CELL DEVELOPMENT | 31 | 1426 | 4.307e-14 | 3.036e-12 |
67 | REGULATION OF PROTEIN LOCALIZATION | 26 | 950 | 4.45e-14 | 3.09e-12 |
68 | SOMITE DEVELOPMENT | 11 | 78 | 4.959e-14 | 3.393e-12 |
69 | REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 15 | 220 | 5.717e-14 | 3.855e-12 |
70 | REGULATION OF PROTEIN IMPORT | 14 | 183 | 8.607e-14 | 5.721e-12 |
71 | REGULATION OF ESTABLISHMENT OF PLANAR POLARITY INVOLVED IN NEURAL TUBE CLOSURE | 7 | 14 | 9.853e-14 | 6.367e-12 |
72 | CONVERGENT EXTENSION | 7 | 14 | 9.853e-14 | 6.367e-12 |
73 | REGULATION OF CELL DEATH | 31 | 1472 | 1.011e-13 | 6.446e-12 |
74 | REGULATION OF BINDING | 16 | 283 | 1.42e-13 | 8.926e-12 |
75 | CELLULAR RESPONSE TO LIPID | 19 | 457 | 1.466e-13 | 9.098e-12 |
76 | REGULATION OF CELL PROLIFERATION | 31 | 1496 | 1.559e-13 | 9.546e-12 |
77 | POSITIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 26 | 1004 | 1.604e-13 | 9.691e-12 |
78 | SOMITOGENESIS | 10 | 62 | 1.807e-13 | 1.064e-11 |
79 | NEGATIVE REGULATION OF EMBRYONIC DEVELOPMENT | 8 | 26 | 1.788e-13 | 1.064e-11 |
80 | REGULATION OF CELL DEVELOPMENT | 24 | 836 | 1.874e-13 | 1.09e-11 |
81 | NEGATIVE REGULATION OF NITROGEN COMPOUND METABOLIC PROCESS | 31 | 1517 | 2.262e-13 | 1.299e-11 |
82 | EMBRYONIC ORGAN DEVELOPMENT | 18 | 406 | 2.346e-13 | 1.331e-11 |
83 | REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 14 | 197 | 2.385e-13 | 1.337e-11 |
84 | BETA CATENIN TCF COMPLEX ASSEMBLY | 9 | 43 | 2.497e-13 | 1.383e-11 |
85 | MIDBRAIN DEVELOPMENT | 11 | 90 | 2.539e-13 | 1.39e-11 |
86 | CELLULAR RESPONSE TO RETINOIC ACID | 10 | 65 | 2.976e-13 | 1.599e-11 |
87 | REGULATION OF JNK CASCADE | 13 | 159 | 2.99e-13 | 1.599e-11 |
88 | REGULATION OF CELL MORPHOGENESIS | 20 | 552 | 3.963e-13 | 2.095e-11 |
89 | REGULATION OF PROTEIN TARGETING | 16 | 307 | 4.966e-13 | 2.596e-11 |
90 | POSITIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 27 | 1152 | 5.212e-13 | 2.694e-11 |
91 | REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 17 | 365 | 5.309e-13 | 2.715e-11 |
92 | SENSORY ORGAN DEVELOPMENT | 19 | 493 | 5.628e-13 | 2.846e-11 |
93 | CELLULAR RESPONSE TO OXYGEN CONTAINING COMPOUND | 23 | 799 | 6.253e-13 | 3.115e-11 |
94 | REGULATION OF RESPONSE TO STRESS | 30 | 1468 | 6.292e-13 | 3.115e-11 |
95 | REGULATION OF TRANSPORT | 33 | 1804 | 6.386e-13 | 3.128e-11 |
96 | DIGESTIVE TRACT MORPHOGENESIS | 9 | 48 | 7.293e-13 | 3.535e-11 |
97 | NEGATIVE REGULATION OF MULTICELLULAR ORGANISMAL PROCESS | 25 | 983 | 7.842e-13 | 3.762e-11 |
98 | REGULATION OF CELLULAR LOCALIZATION | 28 | 1277 | 8.67e-13 | 4.116e-11 |
99 | REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 14 | 218 | 9.57e-13 | 4.498e-11 |
100 | NEGATIVE REGULATION OF GENE EXPRESSION | 30 | 1493 | 9.71e-13 | 4.518e-11 |
101 | REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 17 | 381 | 1.058e-12 | 4.874e-11 |
102 | REGULATION OF MAPK CASCADE | 21 | 660 | 1.137e-12 | 5.134e-11 |
103 | CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 19 | 513 | 1.134e-12 | 5.134e-11 |
104 | POSITIVE REGULATION OF CATALYTIC ACTIVITY | 30 | 1518 | 1.485e-12 | 6.645e-11 |
105 | CELL PROLIFERATION | 21 | 672 | 1.602e-12 | 7.101e-11 |
106 | RESPONSE TO RETINOIC ACID | 11 | 107 | 1.778e-12 | 7.803e-11 |
107 | REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 18 | 470 | 2.761e-12 | 1.2e-10 |
108 | REGULATION OF CELL CYCLE | 24 | 949 | 2.816e-12 | 1.213e-10 |
109 | REGULATION OF JUN KINASE ACTIVITY | 10 | 81 | 2.946e-12 | 1.258e-10 |
110 | EPITHELIAL TO MESENCHYMAL TRANSITION | 9 | 56 | 3.2e-12 | 1.353e-10 |
111 | REGULATION OF STEM CELL DIFFERENTIATION | 11 | 113 | 3.263e-12 | 1.368e-10 |
112 | REGULATION OF INTRACELLULAR TRANSPORT | 20 | 621 | 3.432e-12 | 1.426e-10 |
113 | REGULATION OF CYTOPLASMIC TRANSPORT | 18 | 481 | 4.06e-12 | 1.672e-10 |
114 | HEAD DEVELOPMENT | 21 | 709 | 4.429e-12 | 1.808e-10 |
115 | GASTRULATION | 12 | 155 | 4.971e-12 | 2.011e-10 |
116 | RESPONSE TO LIPID | 23 | 888 | 5.447e-12 | 2.185e-10 |
117 | RESPONSE TO OXYGEN CONTAINING COMPOUND | 28 | 1381 | 5.702e-12 | 2.268e-10 |
118 | POSITIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 12 | 162 | 8.396e-12 | 3.311e-10 |
119 | AXIS SPECIFICATION | 10 | 90 | 8.682e-12 | 3.395e-10 |
120 | IMMUNE RESPONSE REGULATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 15 | 323 | 1.474e-11 | 5.716e-10 |
121 | REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 9 | 67 | 1.735e-11 | 6.67e-10 |
122 | PROTEIN PHOSPHORYLATION | 23 | 944 | 1.876e-11 | 7.154e-10 |
123 | POSITIVE REGULATION OF CELL DEATH | 19 | 605 | 1.996e-11 | 7.552e-10 |
124 | NEGATIVE REGULATION OF CELL DIFFERENTIATION | 19 | 609 | 2.236e-11 | 8.39e-10 |
125 | EMBRYONIC ORGAN MORPHOGENESIS | 14 | 279 | 2.675e-11 | 9.957e-10 |
126 | CENTRAL NERVOUS SYSTEM DEVELOPMENT | 22 | 872 | 2.878e-11 | 1.063e-09 |
127 | POSITIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 22 | 876 | 3.144e-11 | 1.152e-09 |
128 | REPRODUCTIVE SYSTEM DEVELOPMENT | 16 | 408 | 3.636e-11 | 1.322e-09 |
129 | NEGATIVE REGULATION OF MOLECULAR FUNCTION | 24 | 1079 | 4.132e-11 | 1.49e-09 |
130 | SENSORY ORGAN MORPHOGENESIS | 13 | 239 | 5.322e-11 | 1.905e-09 |
131 | MESENCHYME DEVELOPMENT | 12 | 190 | 5.472e-11 | 1.929e-09 |
132 | STEM CELL DIFFERENTIATION | 12 | 190 | 5.472e-11 | 1.929e-09 |
133 | DIGESTIVE SYSTEM DEVELOPMENT | 11 | 148 | 6.314e-11 | 2.209e-09 |
134 | POSITIVE REGULATION OF WNT SIGNALING PATHWAY | 11 | 152 | 8.43e-11 | 2.927e-09 |
135 | REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 20 | 750 | 1.014e-10 | 3.495e-09 |
136 | NEGATIVE REGULATION OF CELL MORPHOGENESIS INVOLVED IN DIFFERENTIATION | 10 | 117 | 1.227e-10 | 4.197e-09 |
137 | INOSITOL PHOSPHATE MEDIATED SIGNALING | 6 | 18 | 1.246e-10 | 4.232e-09 |
138 | REGULATION OF TRANSFERASE ACTIVITY | 22 | 946 | 1.373e-10 | 4.63e-09 |
139 | BRAIN MORPHOGENESIS | 7 | 34 | 1.436e-10 | 4.807e-09 |
140 | REGULATION OF MAP KINASE ACTIVITY | 14 | 319 | 1.577e-10 | 5.242e-09 |
141 | REGULATION OF KINASE ACTIVITY | 20 | 776 | 1.849e-10 | 6.101e-09 |
142 | HEART MORPHOGENESIS | 12 | 212 | 1.953e-10 | 6.401e-09 |
143 | NEGATIVE REGULATION OF CELL DEATH | 21 | 872 | 2.074e-10 | 6.749e-09 |
144 | PHOSPHATE CONTAINING COMPOUND METABOLIC PROCESS | 31 | 1977 | 2.142e-10 | 6.922e-09 |
145 | REGULATION OF PROTEIN BINDING | 11 | 168 | 2.479e-10 | 7.956e-09 |
146 | REGULATION OF ORGANELLE ORGANIZATION | 24 | 1178 | 2.496e-10 | 7.956e-09 |
147 | VASCULATURE DEVELOPMENT | 16 | 469 | 2.832e-10 | 8.964e-09 |
148 | DORSAL VENTRAL PATTERN FORMATION | 9 | 91 | 2.913e-10 | 9.157e-09 |
149 | POSITIVE REGULATION OF CELL DEVELOPMENT | 16 | 472 | 3.108e-10 | 9.706e-09 |
150 | RESPONSE TO GROWTH FACTOR | 16 | 475 | 3.409e-10 | 1.057e-08 |
151 | CELLULAR RESPONSE TO ACID CHEMICAL | 11 | 175 | 3.839e-10 | 1.183e-08 |
152 | POSITIVE REGULATION OF JUN KINASE ACTIVITY | 8 | 63 | 3.873e-10 | 1.186e-08 |
153 | REGULATION OF CELL CYCLE PROCESS | 17 | 558 | 4.187e-10 | 1.273e-08 |
154 | MESENCHYMAL CELL DIFFERENTIATION | 10 | 134 | 4.713e-10 | 1.424e-08 |
155 | REGULATION OF HYDROLASE ACTIVITY | 25 | 1327 | 4.958e-10 | 1.488e-08 |
156 | POSITIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 10 | 135 | 5.071e-10 | 1.513e-08 |
157 | POSITIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 13 | 289 | 5.566e-10 | 1.65e-08 |
158 | NEGATIVE REGULATION OF TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 19 | 740 | 6.051e-10 | 1.782e-08 |
159 | FC EPSILON RECEPTOR SIGNALING PATHWAY | 10 | 142 | 8.338e-10 | 2.44e-08 |
160 | RESPIRATORY SYSTEM DEVELOPMENT | 11 | 197 | 1.352e-09 | 3.932e-08 |
161 | CELL CYCLE PROCESS | 22 | 1081 | 1.685e-09 | 4.869e-08 |
162 | SKELETAL SYSTEM DEVELOPMENT | 15 | 455 | 1.731e-09 | 4.971e-08 |
163 | RESPONSE TO ACID CHEMICAL | 13 | 319 | 1.851e-09 | 5.285e-08 |
164 | POSITIVE REGULATION OF TRANSFERASE ACTIVITY | 17 | 616 | 1.876e-09 | 5.323e-08 |
165 | REGULATION OF CATENIN IMPORT INTO NUCLEUS | 6 | 27 | 1.924e-09 | 5.392e-08 |
166 | AXIS ELONGATION | 6 | 27 | 1.924e-09 | 5.392e-08 |
167 | CELLULAR COMPONENT MORPHOGENESIS | 20 | 900 | 2.418e-09 | 6.738e-08 |
168 | DOPAMINERGIC NEURON DIFFERENTIATION | 6 | 28 | 2.439e-09 | 6.756e-08 |
169 | POSITIVE REGULATION OF STEM CELL DIFFERENTIATION | 7 | 50 | 2.516e-09 | 6.926e-08 |
170 | POSITIVE REGULATION OF MAPK CASCADE | 15 | 470 | 2.688e-09 | 7.358e-08 |
171 | POSITIVE REGULATION OF CANONICAL WNT SIGNALING PATHWAY | 9 | 119 | 3.245e-09 | 8.803e-08 |
172 | PHOSPHORYLATION | 23 | 1228 | 3.254e-09 | 8.803e-08 |
173 | POSITIVE REGULATION OF KINASE ACTIVITY | 15 | 482 | 3.781e-09 | 1.011e-07 |
174 | POSITIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 9 | 121 | 3.762e-09 | 1.011e-07 |
175 | MORPHOGENESIS OF A BRANCHING STRUCTURE | 10 | 167 | 4.047e-09 | 1.076e-07 |
176 | CELL ACTIVATION | 16 | 568 | 4.466e-09 | 1.181e-07 |
177 | APPENDAGE DEVELOPMENT | 10 | 169 | 4.541e-09 | 1.187e-07 |
178 | LIMB DEVELOPMENT | 10 | 169 | 4.541e-09 | 1.187e-07 |
179 | POSITIVE REGULATION OF ORGANELLE ORGANIZATION | 16 | 573 | 5.058e-09 | 1.315e-07 |
180 | OUTFLOW TRACT MORPHOGENESIS | 7 | 56 | 5.715e-09 | 1.477e-07 |
181 | EMBRYONIC AXIS SPECIFICATION | 6 | 33 | 7.043e-09 | 1.811e-07 |
182 | EMBRYONIC PATTERN SPECIFICATION | 7 | 58 | 7.355e-09 | 1.88e-07 |
183 | RESPONSE TO DRUG | 14 | 431 | 7.687e-09 | 1.954e-07 |
184 | POSITIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 13 | 360 | 7.91e-09 | 1.991e-07 |
185 | MUSCLE STRUCTURE DEVELOPMENT | 14 | 432 | 7.916e-09 | 1.991e-07 |
186 | POSITIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 6 | 34 | 8.522e-09 | 2.132e-07 |
187 | POSITIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 15 | 514 | 8.965e-09 | 2.231e-07 |
188 | CELLULAR COMPONENT DISASSEMBLY | 15 | 515 | 9.201e-09 | 2.277e-07 |
189 | MACROMOLECULAR COMPLEX DISASSEMBLY | 10 | 182 | 9.267e-09 | 2.281e-07 |
190 | RHYTHMIC PROCESS | 12 | 298 | 9.334e-09 | 2.286e-07 |
191 | DEVELOPMENTAL PROCESS INVOLVED IN REPRODUCTION | 16 | 602 | 1.015e-08 | 2.474e-07 |
192 | POSITIVE REGULATION OF INTRACELLULAR TRANSPORT | 13 | 370 | 1.096e-08 | 2.656e-07 |
193 | CELL CYCLE | 23 | 1316 | 1.203e-08 | 2.899e-07 |
194 | REGULATION OF MUSCLE ADAPTATION | 7 | 63 | 1.329e-08 | 3.188e-07 |
195 | CELL DEATH | 20 | 1001 | 1.461e-08 | 3.486e-07 |
196 | REGULATION OF MITOTIC CELL CYCLE | 14 | 468 | 2.168e-08 | 5.146e-07 |
197 | DEVELOPMENTAL GROWTH INVOLVED IN MORPHOGENESIS | 8 | 104 | 2.218e-08 | 5.238e-07 |
198 | POSITIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 11 | 258 | 2.253e-08 | 5.294e-07 |
199 | EYE DEVELOPMENT | 12 | 326 | 2.526e-08 | 5.905e-07 |
200 | NEGATIVE REGULATION OF CELL PROLIFERATION | 16 | 643 | 2.551e-08 | 5.934e-07 |
201 | CELLULAR RESPONSE TO ABIOTIC STIMULUS | 11 | 263 | 2.743e-08 | 6.351e-07 |
202 | FC RECEPTOR SIGNALING PATHWAY | 10 | 206 | 3.018e-08 | 6.952e-07 |
203 | POSITIVE REGULATION OF MAP KINASE ACTIVITY | 10 | 207 | 3.16e-08 | 7.243e-07 |
204 | DEVELOPMENTAL GROWTH | 12 | 333 | 3.191e-08 | 7.278e-07 |
205 | SKIN DEVELOPMENT | 10 | 211 | 3.787e-08 | 8.595e-07 |
206 | REGULATION OF IMMUNE SYSTEM PROCESS | 23 | 1403 | 3.946e-08 | 8.912e-07 |
207 | PROTEIN COMPLEX SUBUNIT ORGANIZATION | 24 | 1527 | 4.128e-08 | 9.279e-07 |
208 | MITOTIC CELL CYCLE | 17 | 766 | 4.686e-08 | 1.048e-06 |
209 | CELL CELL SIGNALING | 17 | 767 | 4.775e-08 | 1.063e-06 |
210 | REGULATION OF BMP SIGNALING PATHWAY | 7 | 77 | 5.49e-08 | 1.216e-06 |
211 | POSITIVE REGULATION OF CYTOPLASMIC TRANSPORT | 11 | 282 | 5.594e-08 | 1.234e-06 |
212 | PEPTIDYL THREONINE MODIFICATION | 6 | 46 | 5.684e-08 | 1.248e-06 |
213 | NEGATIVE REGULATION OF CELLULAR COMPONENT ORGANIZATION | 16 | 684 | 5.992e-08 | 1.309e-06 |
214 | NEGATIVE REGULATION OF PROTEIN BINDING | 7 | 79 | 6.57e-08 | 1.428e-06 |
215 | POSITIVE REGULATION OF SEQUENCE SPECIFIC DNA BINDING TRANSCRIPTION FACTOR ACTIVITY | 10 | 228 | 7.851e-08 | 1.699e-06 |
216 | REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 10 | 229 | 8.18e-08 | 1.756e-06 |
217 | REGULATION OF APOPTOTIC SIGNALING PATHWAY | 12 | 363 | 8.192e-08 | 1.756e-06 |
218 | POSITIVE REGULATION OF HYDROLASE ACTIVITY | 18 | 905 | 9.332e-08 | 1.992e-06 |
219 | UROGENITAL SYSTEM DEVELOPMENT | 11 | 299 | 1.012e-07 | 2.151e-06 |
220 | RESPONSE TO CYTOKINE | 16 | 714 | 1.078e-07 | 2.28e-06 |
221 | PALATE DEVELOPMENT | 7 | 85 | 1.095e-07 | 2.304e-06 |
222 | RESPONSE TO ABIOTIC STIMULUS | 19 | 1024 | 1.146e-07 | 2.403e-06 |
223 | NEGATIVE REGULATION OF BINDING | 8 | 131 | 1.35e-07 | 2.803e-06 |
224 | BRANCHING MORPHOGENESIS OF AN EPITHELIAL TUBE | 8 | 131 | 1.35e-07 | 2.803e-06 |
225 | SINGLE ORGANISM CELL ADHESION | 13 | 459 | 1.364e-07 | 2.821e-06 |
226 | REGULATION OF GROWTH | 15 | 633 | 1.383e-07 | 2.847e-06 |
227 | REGULATION OF STEM CELL PROLIFERATION | 7 | 88 | 1.393e-07 | 2.854e-06 |
228 | POSITIVE REGULATION OF TRANSPORT | 18 | 936 | 1.542e-07 | 3.147e-06 |
229 | CALCIUM MEDIATED SIGNALING | 7 | 90 | 1.627e-07 | 3.306e-06 |
230 | EYE MORPHOGENESIS | 8 | 136 | 1.803e-07 | 3.647e-06 |
231 | REGULATION OF CELL GROWTH | 12 | 391 | 1.829e-07 | 3.683e-06 |
232 | REGULATION OF PROTEIN CATABOLIC PROCESS | 12 | 393 | 1.932e-07 | 3.874e-06 |
233 | GLAND DEVELOPMENT | 12 | 395 | 2.04e-07 | 4.074e-06 |
234 | REPRODUCTION | 21 | 1297 | 2.169e-07 | 4.313e-06 |
235 | LEUKOCYTE CELL CELL ADHESION | 10 | 255 | 2.226e-07 | 4.407e-06 |
236 | REGULATION OF IMMUNE RESPONSE | 17 | 858 | 2.369e-07 | 4.671e-06 |
237 | REGULATION OF CELL FATE SPECIFICATION | 4 | 13 | 2.658e-07 | 5.218e-06 |
238 | CARDIAC CHAMBER DEVELOPMENT | 8 | 144 | 2.799e-07 | 5.449e-06 |
239 | RESPONSE TO TRANSFORMING GROWTH FACTOR BETA | 8 | 144 | 2.799e-07 | 5.449e-06 |
240 | STEM CELL PROLIFERATION | 6 | 60 | 2.889e-07 | 5.562e-06 |
241 | NEGATIVE REGULATION OF PROTEIN METABOLIC PROCESS | 19 | 1087 | 2.884e-07 | 5.562e-06 |
242 | POSITIVE REGULATION OF CELL CYCLE | 11 | 332 | 2.893e-07 | 5.562e-06 |
243 | POSITIVE REGULATION OF PROTEIN CATABOLIC PROCESS | 10 | 263 | 2.96e-07 | 5.668e-06 |
244 | REGULATION OF ORGAN FORMATION | 5 | 32 | 3.017e-07 | 5.754e-06 |
245 | GROWTH | 12 | 410 | 3.04e-07 | 5.754e-06 |
246 | REGULATION OF CELLULAR COMPONENT MOVEMENT | 16 | 771 | 3.042e-07 | 5.754e-06 |
247 | EMBRYONIC DIGIT MORPHOGENESIS | 6 | 61 | 3.192e-07 | 6.014e-06 |
248 | RESPONSE TO ENDOGENOUS STIMULUS | 22 | 1450 | 3.208e-07 | 6.019e-06 |
249 | SEX DIFFERENTIATION | 10 | 266 | 3.286e-07 | 6.14e-06 |
250 | CAMERA TYPE EYE MORPHOGENESIS | 7 | 101 | 3.599e-07 | 6.698e-06 |
251 | LYMPHOCYTE ACTIVATION | 11 | 342 | 3.885e-07 | 7.201e-06 |
252 | REGULATION OF MESENCHYMAL CELL PROLIFERATION | 5 | 34 | 4.14e-07 | 7.644e-06 |
253 | LOCOMOTION | 19 | 1114 | 4.196e-07 | 7.718e-06 |
254 | CARDIAC CHAMBER MORPHOGENESIS | 7 | 104 | 4.396e-07 | 8.022e-06 |
255 | POSITIVE REGULATION OF PROTEIN IMPORT | 7 | 104 | 4.396e-07 | 8.022e-06 |
256 | POSITIVE REGULATION OF EPITHELIAL CELL PROLIFERATION | 8 | 154 | 4.678e-07 | 8.503e-06 |
257 | FAT CELL DIFFERENTIATION | 7 | 106 | 5.007e-07 | 9.065e-06 |
258 | REGULATION OF MESODERM DEVELOPMENT | 4 | 15 | 5.039e-07 | 9.087e-06 |
259 | LENS DEVELOPMENT IN CAMERA TYPE EYE | 6 | 66 | 5.13e-07 | 9.217e-06 |
260 | FOREBRAIN DEVELOPMENT | 11 | 357 | 5.938e-07 | 1.063e-05 |
261 | REGULATION OF PROTEOLYSIS | 15 | 711 | 6.08e-07 | 1.084e-05 |
262 | REGULATION OF EPITHELIAL CELL PROLIFERATION | 10 | 285 | 6.182e-07 | 1.098e-05 |
263 | SECOND MESSENGER MEDIATED SIGNALING | 8 | 160 | 6.258e-07 | 1.105e-05 |
264 | POSITIVE REGULATION OF CELL PROLIFERATION | 16 | 814 | 6.267e-07 | 1.105e-05 |
265 | FORMATION OF PRIMARY GERM LAYER | 7 | 110 | 6.444e-07 | 1.131e-05 |
266 | PARAXIAL MESODERM DEVELOPMENT | 4 | 16 | 6.695e-07 | 1.171e-05 |
267 | RESPONSE TO ALCOHOL | 11 | 362 | 6.809e-07 | 1.187e-05 |
268 | BLOOD VESSEL MORPHOGENESIS | 11 | 364 | 7.188e-07 | 1.248e-05 |
269 | MESENCHYME MORPHOGENESIS | 5 | 38 | 7.363e-07 | 1.274e-05 |
270 | NEGATIVE REGULATION OF NUCLEOCYTOPLASMIC TRANSPORT | 6 | 71 | 7.943e-07 | 1.364e-05 |
271 | SKIN EPIDERMIS DEVELOPMENT | 6 | 71 | 7.943e-07 | 1.364e-05 |
272 | REGULATION OF CATABOLIC PROCESS | 15 | 731 | 8.612e-07 | 1.473e-05 |
273 | REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 4 | 17 | 8.725e-07 | 1.476e-05 |
274 | REGULATION OF CHROMATIN BINDING | 4 | 17 | 8.725e-07 | 1.476e-05 |
275 | ESTABLISHMENT OF TISSUE POLARITY | 4 | 17 | 8.725e-07 | 1.476e-05 |
276 | NEGATIVE REGULATION OF TRANSPORT | 12 | 458 | 9.803e-07 | 1.653e-05 |
277 | NEGATIVE REGULATION OF CELL GROWTH | 8 | 170 | 9.904e-07 | 1.664e-05 |
278 | MESODERM DEVELOPMENT | 7 | 118 | 1.037e-06 | 1.729e-05 |
279 | POSITIVE REGULATION OF APOPTOTIC SIGNALING PATHWAY | 8 | 171 | 1.035e-06 | 1.729e-05 |
280 | REGULATION OF VASCULATURE DEVELOPMENT | 9 | 233 | 1.055e-06 | 1.752e-05 |
281 | NEGATIVE REGULATION OF CELL DEVELOPMENT | 10 | 303 | 1.078e-06 | 1.785e-05 |
282 | POST ANAL TAIL MORPHOGENESIS | 4 | 18 | 1.118e-06 | 1.845e-05 |
283 | NEGATIVE REGULATION OF GROWTH | 9 | 236 | 1.173e-06 | 1.928e-05 |
284 | REGULATION OF CELLULAR RESPONSE TO HEAT | 6 | 76 | 1.191e-06 | 1.951e-05 |
285 | NEGATIVE REGULATION OF BMP SIGNALING PATHWAY | 5 | 42 | 1.23e-06 | 2.009e-05 |
286 | IN UTERO EMBRYONIC DEVELOPMENT | 10 | 311 | 1.364e-06 | 2.219e-05 |
287 | T CELL DIFFERENTIATION | 7 | 123 | 1.372e-06 | 2.224e-05 |
288 | MORPHOGENESIS OF AN EPITHELIAL SHEET | 5 | 43 | 1.387e-06 | 2.241e-05 |
289 | REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 4 | 19 | 1.411e-06 | 2.272e-05 |
290 | KIDNEY EPITHELIUM DEVELOPMENT | 7 | 125 | 1.529e-06 | 2.453e-05 |
291 | LABYRINTHINE LAYER DEVELOPMENT | 5 | 44 | 1.56e-06 | 2.494e-05 |
292 | RESPONSE TO UV | 7 | 126 | 1.613e-06 | 2.571e-05 |
293 | POSITIVE REGULATION OF CELL CYCLE PROCESS | 9 | 247 | 1.709e-06 | 2.714e-05 |
294 | TRACHEA DEVELOPMENT | 4 | 20 | 1.758e-06 | 2.773e-05 |
295 | POSITIVE REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 4 | 20 | 1.758e-06 | 2.773e-05 |
296 | REGULATION OF CELL CYCLE PHASE TRANSITION | 10 | 321 | 1.813e-06 | 2.85e-05 |
297 | KIDNEY MORPHOGENESIS | 6 | 82 | 1.867e-06 | 2.924e-05 |
298 | POSITIVE REGULATION OF PROTEIN LOCALIZATION TO NUCLEUS | 7 | 129 | 1.889e-06 | 2.949e-05 |
299 | IMMUNE SYSTEM DEVELOPMENT | 13 | 582 | 1.982e-06 | 3.079e-05 |
300 | SIGNAL TRANSDUCTION BY PROTEIN PHOSPHORYLATION | 11 | 404 | 1.985e-06 | 3.079e-05 |
301 | HAIR CYCLE | 6 | 83 | 2.005e-06 | 3.089e-05 |
302 | MOLTING CYCLE | 6 | 83 | 2.005e-06 | 3.089e-05 |
303 | COCHLEA MORPHOGENESIS | 4 | 21 | 2.164e-06 | 3.323e-05 |
304 | CELLULAR RESPONSE TO ENDOGENOUS STIMULUS | 17 | 1008 | 2.198e-06 | 3.365e-05 |
305 | CARDIAC SEPTUM DEVELOPMENT | 6 | 85 | 2.306e-06 | 3.518e-05 |
306 | PROTEIN COMPLEX BIOGENESIS | 18 | 1132 | 2.426e-06 | 3.665e-05 |
307 | ANTERIOR POSTERIOR AXIS SPECIFICATION | 5 | 48 | 2.424e-06 | 3.665e-05 |
308 | PROTEIN COMPLEX ASSEMBLY | 18 | 1132 | 2.426e-06 | 3.665e-05 |
309 | LEUKOCYTE ACTIVATION | 11 | 414 | 2.513e-06 | 3.778e-05 |
310 | RESPONSE TO METAL ION | 10 | 333 | 2.517e-06 | 3.778e-05 |
311 | CONNECTIVE TISSUE DEVELOPMENT | 8 | 194 | 2.665e-06 | 3.987e-05 |
312 | CARDIAC SEPTUM MORPHOGENESIS | 5 | 49 | 2.69e-06 | 4.012e-05 |
313 | NEGATIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 9 | 262 | 2.774e-06 | 4.124e-05 |
314 | CELLULAR RESPONSE TO RADIATION | 7 | 137 | 2.823e-06 | 4.184e-05 |
315 | BIOLOGICAL ADHESION | 17 | 1032 | 3.019e-06 | 4.46e-05 |
316 | CELL CELL ADHESION | 13 | 608 | 3.202e-06 | 4.714e-05 |
317 | NEGATIVE REGULATION OF MITOTIC CELL CYCLE | 8 | 199 | 3.22e-06 | 4.718e-05 |
318 | MESONEPHROS DEVELOPMENT | 6 | 90 | 3.225e-06 | 4.718e-05 |
319 | POSITIVE REGULATION OF FAT CELL DIFFERENTIATION | 5 | 51 | 3.291e-06 | 4.8e-05 |
320 | ESTABLISHMENT OR MAINTENANCE OF CELL POLARITY | 7 | 141 | 3.419e-06 | 4.972e-05 |
321 | PROTEASOMAL PROTEIN CATABOLIC PROCESS | 9 | 271 | 3.655e-06 | 5.298e-05 |
322 | INNER EAR MORPHOGENESIS | 6 | 92 | 3.667e-06 | 5.299e-05 |
323 | NEGATIVE REGULATION OF PROTEIN MODIFICATION PROCESS | 13 | 616 | 3.692e-06 | 5.318e-05 |
324 | NEGATIVE REGULATION OF CELL CYCLE | 11 | 433 | 3.864e-06 | 5.549e-05 |
325 | REGULATION OF MORPHOGENESIS OF A BRANCHING STRUCTURE | 5 | 53 | 3.992e-06 | 5.715e-05 |
326 | CELL MOTILITY | 15 | 835 | 4.432e-06 | 6.267e-05 |
327 | NEGATIVE REGULATION OF INTRACELLULAR PROTEIN TRANSPORT | 6 | 95 | 4.421e-06 | 6.267e-05 |
328 | REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 6 | 95 | 4.421e-06 | 6.267e-05 |
329 | LOCALIZATION OF CELL | 15 | 835 | 4.432e-06 | 6.267e-05 |
330 | CARTILAGE DEVELOPMENT | 7 | 147 | 4.507e-06 | 6.335e-05 |
331 | REGULATION OF CHROMOSOME ORGANIZATION | 9 | 278 | 4.497e-06 | 6.335e-05 |
332 | NEGATIVE REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION | 8 | 209 | 4.627e-06 | 6.453e-05 |
333 | REGULATION OF CELL ADHESION | 13 | 629 | 4.632e-06 | 6.453e-05 |
334 | LYMPHOCYTE DIFFERENTIATION | 8 | 209 | 4.627e-06 | 6.453e-05 |
335 | PEPTIDYL SERINE MODIFICATION | 7 | 148 | 4.713e-06 | 6.527e-05 |
336 | MALE SEX DIFFERENTIATION | 7 | 148 | 4.713e-06 | 6.527e-05 |
337 | IMMUNE SYSTEM PROCESS | 24 | 1984 | 4.83e-06 | 6.669e-05 |
338 | REGULATION OF CELL FATE COMMITMENT | 4 | 26 | 5.314e-06 | 7.315e-05 |
339 | POSITIVE REGULATION OF PROTEOLYSIS | 10 | 363 | 5.405e-06 | 7.419e-05 |
340 | NEGATIVE REGULATION OF PHOSPHORUS METABOLIC PROCESS | 12 | 541 | 5.465e-06 | 7.458e-05 |
341 | NEGATIVE REGULATION OF PHOSPHATE METABOLIC PROCESS | 12 | 541 | 5.465e-06 | 7.458e-05 |
342 | REGULATION OF MUSCLE CELL DIFFERENTIATION | 7 | 152 | 5.62e-06 | 7.647e-05 |
343 | REGULATION OF DEVELOPMENTAL GROWTH | 9 | 289 | 6.156e-06 | 8.351e-05 |
344 | DEVELOPMENTAL INDUCTION | 4 | 27 | 6.216e-06 | 8.36e-05 |
345 | RESPONSE TO LITHIUM ION | 4 | 27 | 6.216e-06 | 8.36e-05 |
346 | POSITIVE REGULATION OF MESENCHYMAL CELL PROLIFERATION | 4 | 27 | 6.216e-06 | 8.36e-05 |
347 | LEUKOCYTE DIFFERENTIATION | 9 | 292 | 6.69e-06 | 8.946e-05 |
348 | NEGATIVE REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 6 | 102 | 6.68e-06 | 8.946e-05 |
349 | REGULATION OF NEURON DIFFERENTIATION | 12 | 554 | 6.951e-06 | 9.267e-05 |
350 | REGULATION OF MUSCLE TISSUE DEVELOPMENT | 6 | 103 | 7.067e-06 | 9.342e-05 |
351 | REGULATION OF MUSCLE ORGAN DEVELOPMENT | 6 | 103 | 7.067e-06 | 9.342e-05 |
352 | STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 6 | 103 | 7.067e-06 | 9.342e-05 |
353 | VENTRICULAR SEPTUM MORPHOGENESIS | 4 | 28 | 7.227e-06 | 9.473e-05 |
354 | GASTRULATION WITH MOUTH FORMING SECOND | 4 | 28 | 7.227e-06 | 9.473e-05 |
355 | MORPHOGENESIS OF A POLARIZED EPITHELIUM | 4 | 28 | 7.227e-06 | 9.473e-05 |
356 | CELLULAR RESPONSE TO ORGANIC CYCLIC COMPOUND | 11 | 465 | 7.597e-06 | 9.93e-05 |
357 | REGULATION OF CELLULAR COMPONENT BIOGENESIS | 14 | 767 | 8.007e-06 | 0.0001044 |
358 | POSITIVE REGULATION OF STEM CELL PROLIFERATION | 5 | 61 | 8.044e-06 | 0.0001046 |
359 | REGULATION OF FAT CELL DIFFERENTIATION | 6 | 106 | 8.341e-06 | 0.0001081 |
360 | REGULATION OF CARTILAGE DEVELOPMENT | 5 | 63 | 9.437e-06 | 0.0001216 |
361 | REGULATION OF EPIDERMIS DEVELOPMENT | 5 | 63 | 9.437e-06 | 0.0001216 |
362 | CENTRAL NERVOUS SYSTEM NEURON DIFFERENTIATION | 7 | 166 | 1.002e-05 | 0.0001288 |
363 | POSITIVE REGULATION OF CATABOLIC PROCESS | 10 | 395 | 1.131e-05 | 0.0001449 |
364 | REGULATION OF ACTIN FILAMENT BASED PROCESS | 9 | 312 | 1.138e-05 | 0.0001455 |
365 | EAR MORPHOGENESIS | 6 | 112 | 1.145e-05 | 0.0001455 |
366 | REGULATION OF OSTEOBLAST DIFFERENTIATION | 6 | 112 | 1.145e-05 | 0.0001455 |
367 | MUSCLE CELL DIFFERENTIATION | 8 | 237 | 1.161e-05 | 0.0001472 |
368 | CELLULAR RESPONSE TO UV | 5 | 66 | 1.187e-05 | 0.0001497 |
369 | MESODERM MORPHOGENESIS | 5 | 66 | 1.187e-05 | 0.0001497 |
370 | POSITIVE REGULATION OF GROWTH | 8 | 238 | 1.197e-05 | 0.0001505 |
371 | PATTERNING OF BLOOD VESSELS | 4 | 32 | 1.252e-05 | 0.000157 |
372 | MOVEMENT OF CELL OR SUBCELLULAR COMPONENT | 18 | 1275 | 1.259e-05 | 0.0001574 |
373 | REGULATION OF CELL SUBSTRATE ADHESION | 7 | 173 | 1.311e-05 | 0.0001635 |
374 | CELLULAR RESPONSE TO ALCOHOL | 6 | 115 | 1.332e-05 | 0.0001653 |
375 | NEPHRON DEVELOPMENT | 6 | 115 | 1.332e-05 | 0.0001653 |
376 | EPITHELIAL CELL DIFFERENTIATION | 11 | 495 | 1.364e-05 | 0.0001688 |
377 | POSITIVE REGULATION OF NON CANONICAL WNT SIGNALING PATHWAY | 3 | 11 | 1.417e-05 | 0.0001743 |
378 | POSITIVE REGULATION OF EMBRYONIC DEVELOPMENT | 4 | 33 | 1.42e-05 | 0.0001743 |
379 | POSITIVE REGULATION OF NFAT PROTEIN IMPORT INTO NUCLEUS | 3 | 11 | 1.417e-05 | 0.0001743 |
380 | POSITIVE REGULATION OF CELLULAR COMPONENT BIOGENESIS | 10 | 406 | 1.434e-05 | 0.0001756 |
381 | NEGATIVE REGULATION OF CYTOPLASMIC TRANSPORT | 6 | 117 | 1.47e-05 | 0.0001795 |
382 | REGULATION OF CYTOSKELETON ORGANIZATION | 11 | 502 | 1.554e-05 | 0.0001893 |
383 | REGULATION OF OSSIFICATION | 7 | 178 | 1.577e-05 | 0.0001916 |
384 | PROTEIN DESTABILIZATION | 4 | 34 | 1.604e-05 | 0.0001943 |
385 | CELLULAR RESPONSE TO STRESS | 20 | 1565 | 1.646e-05 | 0.000199 |
386 | RESPONSE TO RADIATION | 10 | 413 | 1.661e-05 | 0.0002002 |
387 | ENDODERM DEVELOPMENT | 5 | 71 | 1.699e-05 | 0.0002038 |
388 | CELL FATE SPECIFICATION | 5 | 71 | 1.699e-05 | 0.0002038 |
389 | NEGATIVE REGULATION OF CELLULAR RESPONSE TO GROWTH FACTOR STIMULUS | 6 | 121 | 1.781e-05 | 0.000213 |
390 | REGULATION OF GASTRULATION | 4 | 35 | 1.804e-05 | 0.0002153 |
391 | REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 6 | 122 | 1.866e-05 | 0.0002221 |
392 | TRACHEA MORPHOGENESIS | 3 | 12 | 1.883e-05 | 0.0002229 |
393 | REGULATION OF WNT SIGNALING PATHWAY PLANAR CELL POLARITY PATHWAY | 3 | 12 | 1.883e-05 | 0.0002229 |
394 | NEGATIVE REGULATION OF CATALYTIC ACTIVITY | 14 | 829 | 1.915e-05 | 0.0002262 |
395 | PANCREAS DEVELOPMENT | 5 | 73 | 1.947e-05 | 0.0002287 |
396 | EMBRYONIC HEART TUBE DEVELOPMENT | 5 | 73 | 1.947e-05 | 0.0002287 |
397 | REGULATION OF PEPTIDE TRANSPORT | 8 | 256 | 2.025e-05 | 0.0002368 |
398 | POSITIVE REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 36 | 2.023e-05 | 0.0002368 |
399 | TRANSCRIPTION FROM RNA POLYMERASE II PROMOTER | 13 | 724 | 2.074e-05 | 0.0002418 |
400 | NEURAL CREST CELL DIFFERENTIATION | 5 | 75 | 2.221e-05 | 0.0002584 |
401 | NEGATIVE REGULATION OF PROTEIN SERINE THREONINE KINASE ACTIVITY | 6 | 126 | 2.241e-05 | 0.0002601 |
402 | REGULATION OF MUSCLE HYPERTROPHY | 4 | 37 | 2.26e-05 | 0.0002616 |
403 | PROTEIN DEPHOSPHORYLATION | 7 | 190 | 2.402e-05 | 0.0002773 |
404 | HEMATOPOIETIC STEM CELL PROLIFERATION | 3 | 13 | 2.439e-05 | 0.0002796 |
405 | REGULATION OF SKELETAL MUSCLE ADAPTATION | 3 | 13 | 2.439e-05 | 0.0002796 |
406 | REGULATION OF BICELLULAR TIGHT JUNCTION ASSEMBLY | 3 | 13 | 2.439e-05 | 0.0002796 |
407 | NEGATIVE REGULATION OF LOCOMOTION | 8 | 263 | 2.457e-05 | 0.0002809 |
408 | CELLULAR RESPONSE TO EXTERNAL STIMULUS | 8 | 264 | 2.525e-05 | 0.0002872 |
409 | REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 5 | 77 | 2.525e-05 | 0.0002872 |
410 | RENAL TUBULE DEVELOPMENT | 5 | 78 | 2.688e-05 | 0.0003051 |
411 | NEGATIVE REGULATION OF PEPTIDYL TYROSINE PHOSPHORYLATION | 4 | 39 | 2.796e-05 | 0.0003157 |
412 | COCHLEA DEVELOPMENT | 4 | 39 | 2.796e-05 | 0.0003157 |
413 | REGULATION OF MUSCLE SYSTEM PROCESS | 7 | 195 | 2.837e-05 | 0.0003197 |
414 | MAINTENANCE OF CELL NUMBER | 6 | 132 | 2.916e-05 | 0.0003277 |
415 | CELL MIGRATION INVOLVED IN GASTRULATION | 3 | 14 | 3.095e-05 | 0.000347 |
416 | REGULATION OF CELL DIVISION | 8 | 272 | 3.123e-05 | 0.0003493 |
417 | REGULATION OF FIBROBLAST PROLIFERATION | 5 | 81 | 3.228e-05 | 0.0003602 |
418 | NEGATIVE REGULATION OF CELLULAR PROTEIN LOCALIZATION | 6 | 135 | 3.31e-05 | 0.0003684 |
419 | SKELETAL SYSTEM MORPHOGENESIS | 7 | 201 | 3.444e-05 | 0.0003824 |
420 | EMBRYONIC PLACENTA DEVELOPMENT | 5 | 83 | 3.632e-05 | 0.0004024 |
421 | PLACENTA DEVELOPMENT | 6 | 138 | 3.745e-05 | 0.0004139 |
422 | GENITALIA DEVELOPMENT | 4 | 42 | 3.765e-05 | 0.0004152 |
423 | RESPONSE TO LIGHT STIMULUS | 8 | 280 | 3.837e-05 | 0.000422 |
424 | NEGATIVE REGULATION OF DENDRITE MORPHOGENESIS | 3 | 15 | 3.856e-05 | 0.0004231 |
425 | MITOTIC CELL CYCLE CHECKPOINT | 6 | 139 | 3.9e-05 | 0.000427 |
426 | NEGATIVE REGULATION OF STEM CELL DIFFERENTIATION | 4 | 43 | 4.137e-05 | 0.0004488 |
427 | REGULATION OF GLYCOPROTEIN METABOLIC PROCESS | 4 | 43 | 4.137e-05 | 0.0004488 |
428 | REGULATION OF MUSCLE CELL APOPTOTIC PROCESS | 4 | 43 | 4.137e-05 | 0.0004488 |
429 | REGULATION OF MITOCHONDRIAL OUTER MEMBRANE PERMEABILIZATION INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 4 | 43 | 4.137e-05 | 0.0004488 |
430 | REGULATION OF TRANSMEMBRANE RECEPTOR PROTEIN SERINE THREONINE KINASE SIGNALING PATHWAY | 7 | 207 | 4.153e-05 | 0.0004494 |
431 | MACROMOLECULAR COMPLEX ASSEMBLY | 18 | 1398 | 4.296e-05 | 0.0004638 |
432 | POSITIVE REGULATION OF CYTOKINE PRODUCTION | 9 | 370 | 4.349e-05 | 0.0004684 |
433 | REGULATION OF CYTOKINE PRODUCTION | 11 | 563 | 4.442e-05 | 0.0004773 |
434 | NEGATIVE REGULATION OF INTRACELLULAR TRANSPORT | 6 | 143 | 4.572e-05 | 0.0004902 |
435 | MORPHOGENESIS OF AN ENDOTHELIUM | 3 | 16 | 4.73e-05 | 0.0005036 |
436 | ORGAN INDUCTION | 3 | 16 | 4.73e-05 | 0.0005036 |
437 | CELL SURFACE RECEPTOR SIGNALING PATHWAY INVOLVED IN HEART DEVELOPMENT | 3 | 16 | 4.73e-05 | 0.0005036 |
438 | NEGATIVE REGULATION OF CELL PROJECTION ORGANIZATION | 6 | 144 | 4.754e-05 | 0.0005038 |
439 | REGULATION OF GTPASE ACTIVITY | 12 | 673 | 4.748e-05 | 0.0005038 |
440 | THYMOCYTE AGGREGATION | 4 | 45 | 4.961e-05 | 0.0005234 |
441 | T CELL DIFFERENTIATION IN THYMUS | 4 | 45 | 4.961e-05 | 0.0005234 |
442 | WOUND HEALING | 10 | 470 | 4.978e-05 | 0.000524 |
443 | ANGIOGENESIS | 8 | 293 | 5.285e-05 | 0.0005551 |
444 | REGULATION OF CELL CYCLE G1 S PHASE TRANSITION | 6 | 147 | 5.334e-05 | 0.0005589 |
445 | ENDOTHELIUM DEVELOPMENT | 5 | 90 | 5.364e-05 | 0.0005609 |
446 | DEVELOPMENT OF PRIMARY SEXUAL CHARACTERISTICS | 7 | 216 | 5.438e-05 | 0.0005673 |
447 | REGULATION OF PROTEASOMAL UBIQUITIN DEPENDENT PROTEIN CATABOLIC PROCESS | 6 | 148 | 5.539e-05 | 0.0005766 |
448 | CELLULAR RESPONSE TO LIGHT STIMULUS | 5 | 91 | 5.656e-05 | 0.0005874 |
449 | CELLULAR RESPONSE TO LITHIUM ION | 3 | 17 | 5.725e-05 | 0.0005927 |
450 | REGULATION OF HORMONE LEVELS | 10 | 478 | 5.732e-05 | 0.0005927 |
451 | RESPONSE TO ORGANIC CYCLIC COMPOUND | 14 | 917 | 5.769e-05 | 0.0005952 |
452 | RESPONSE TO INORGANIC SUBSTANCE | 10 | 479 | 5.833e-05 | 0.0006005 |
453 | NEPHRON EPITHELIUM DEVELOPMENT | 5 | 93 | 6.276e-05 | 0.0006438 |
454 | REGULATION OF PROTEIN STABILITY | 7 | 221 | 6.282e-05 | 0.0006438 |
455 | PALLIUM DEVELOPMENT | 6 | 153 | 6.663e-05 | 0.0006814 |
456 | PERICARDIUM DEVELOPMENT | 3 | 18 | 6.847e-05 | 0.0006987 |
457 | AMEBOIDAL TYPE CELL MIGRATION | 6 | 154 | 6.909e-05 | 0.0007034 |
458 | FACE DEVELOPMENT | 4 | 50 | 7.538e-05 | 0.0007625 |
459 | ENDODERM FORMATION | 4 | 50 | 7.538e-05 | 0.0007625 |
460 | RHO PROTEIN SIGNAL TRANSDUCTION | 4 | 50 | 7.538e-05 | 0.0007625 |
461 | TELENCEPHALON DEVELOPMENT | 7 | 228 | 7.641e-05 | 0.0007713 |
462 | RESPONSE TO OXYGEN LEVELS | 8 | 311 | 8.019e-05 | 0.0008076 |
463 | POSITIVE REGULATION OF TRANSCRIPTION FACTOR IMPORT INTO NUCLEUS | 4 | 51 | 8.151e-05 | 0.0008192 |
464 | REGULATION OF SYNAPSE STRUCTURE OR ACTIVITY | 7 | 232 | 8.52e-05 | 0.0008544 |
465 | CELLULAR RESPONSE TO CYTOKINE STIMULUS | 11 | 606 | 8.587e-05 | 0.0008592 |
466 | REGULATION OF SMOOTH MUSCLE CELL PROLIFERATION | 5 | 100 | 8.87e-05 | 0.0008857 |
467 | CELLULAR RESPONSE TO BIOTIC STIMULUS | 6 | 163 | 9.457e-05 | 0.0009409 |
468 | MAMMARY GLAND EPITHELIUM DEVELOPMENT | 4 | 53 | 9.486e-05 | 0.0009409 |
469 | TONGUE DEVELOPMENT | 3 | 20 | 9.504e-05 | 0.0009409 |
470 | MESONEPHRIC TUBULE MORPHOGENESIS | 4 | 53 | 9.486e-05 | 0.0009409 |
471 | REGULATION OF CIRCADIAN RHYTHM | 5 | 103 | 0.0001021 | 0.001007 |
472 | VENTRICULAR SEPTUM DEVELOPMENT | 4 | 54 | 0.0001021 | 0.001007 |
473 | POSITIVE REGULATION OF MITOCHONDRION ORGANIZATION | 6 | 167 | 0.0001081 | 0.001063 |
474 | CEREBRAL CORTEX DEVELOPMENT | 5 | 105 | 0.0001118 | 0.001093 |
475 | RESPONSE TO CARBOHYDRATE | 6 | 168 | 0.0001117 | 0.001093 |
476 | ODONTOGENESIS | 5 | 105 | 0.0001118 | 0.001093 |
477 | INNATE IMMUNE RESPONSE ACTIVATING CELL SURFACE RECEPTOR SIGNALING PATHWAY | 5 | 106 | 0.0001169 | 0.001138 |
478 | CARDIAC VENTRICLE DEVELOPMENT | 5 | 106 | 0.0001169 | 0.001138 |
479 | NEGATIVE REGULATION OF PHOSPHORYLATION | 9 | 422 | 0.0001189 | 0.001155 |
480 | PROTEIN LOCALIZATION | 20 | 1805 | 0.0001235 | 0.001197 |
481 | POSITIVE REGULATION OF MUSCLE HYPERTROPHY | 3 | 22 | 0.0001276 | 0.001225 |
482 | SOMATIC STEM CELL DIVISION | 3 | 22 | 0.0001276 | 0.001225 |
483 | POSITIVE REGULATION OF CARDIAC MUSCLE HYPERTROPHY | 3 | 22 | 0.0001276 | 0.001225 |
484 | REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 5 | 108 | 0.0001277 | 0.001225 |
485 | EMBRYONIC PLACENTA MORPHOGENESIS | 3 | 22 | 0.0001276 | 0.001225 |
486 | NEGATIVE REGULATION OF KINASE ACTIVITY | 7 | 250 | 0.0001356 | 0.001298 |
487 | RESPONSE TO EXTERNAL STIMULUS | 20 | 1821 | 0.0001393 | 0.001331 |
488 | VASCULOGENESIS | 4 | 59 | 0.0001444 | 0.001377 |
489 | NEGATIVE REGULATION OF EPITHELIAL TO MESENCHYMAL TRANSITION | 3 | 23 | 0.0001462 | 0.001388 |
490 | EPIDERMIS DEVELOPMENT | 7 | 253 | 0.0001459 | 0.001388 |
491 | MITOCHONDRIAL TRANSPORT | 6 | 177 | 0.0001486 | 0.001408 |
492 | CELL CYCLE PHASE TRANSITION | 7 | 255 | 0.0001532 | 0.001449 |
493 | CHROMATIN MODIFICATION | 10 | 539 | 0.000154 | 0.00145 |
494 | CHONDROCYTE DIFFERENTIATION | 4 | 60 | 0.0001542 | 0.00145 |
495 | REGULATION OF PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 4 | 60 | 0.0001542 | 0.00145 |
496 | POSITIVE REGULATION OF NERVOUS SYSTEM DEVELOPMENT | 9 | 437 | 0.0001545 | 0.00145 |
497 | REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 6 | 181 | 0.0001678 | 0.001571 |
498 | NEURON PROJECTION DEVELOPMENT | 10 | 545 | 0.0001685 | 0.001574 |
499 | RESPONSE TO INTERLEUKIN 1 | 5 | 115 | 0.0001715 | 0.001596 |
500 | RESPONSE TO CALCIUM ION | 5 | 115 | 0.0001715 | 0.001596 |
501 | RESPONSE TO HORMONE | 13 | 893 | 0.0001746 | 0.001621 |
502 | REGULATION OF SMOOTHENED SIGNALING PATHWAY | 4 | 62 | 0.0001752 | 0.001621 |
503 | EMBRYONIC HEART TUBE MORPHOGENESIS | 4 | 62 | 0.0001752 | 0.001621 |
504 | REGULATION OF HORMONE SECRETION | 7 | 262 | 0.0001809 | 0.00167 |
505 | SPECIFICATION OF SYMMETRY | 5 | 117 | 0.0001859 | 0.00171 |
506 | MAMMARY GLAND DEVELOPMENT | 5 | 117 | 0.0001859 | 0.00171 |
507 | CHROMATIN ORGANIZATION | 11 | 663 | 0.0001888 | 0.001733 |
508 | EPITHELIAL CELL DEVELOPMENT | 6 | 186 | 0.0001945 | 0.001782 |
509 | REGULATION OF DENDRITE DEVELOPMENT | 5 | 120 | 0.0002092 | 0.001913 |
510 | NEGATIVE REGULATION OF CARTILAGE DEVELOPMENT | 3 | 26 | 0.0002126 | 0.001939 |
511 | RESPONSE TO WOUNDING | 10 | 563 | 0.0002189 | 0.001989 |
512 | POSITIVE REGULATION OF IMMUNE RESPONSE | 10 | 563 | 0.0002189 | 0.001989 |
513 | SOMATIC STEM CELL POPULATION MAINTENANCE | 4 | 66 | 0.0002233 | 0.002025 |
514 | NEGATIVE REGULATION OF NEURON DIFFERENTIATION | 6 | 191 | 0.0002245 | 0.002032 |
515 | EMBRYONIC SKELETAL SYSTEM DEVELOPMENT | 5 | 122 | 0.000226 | 0.002042 |
516 | CELLULAR RESPONSE TO DRUG | 4 | 67 | 0.0002367 | 0.00213 |
517 | REGULATION OF SISTER CHROMATID SEGREGATION | 4 | 67 | 0.0002367 | 0.00213 |
518 | REGULATION OF CELLULAR PROTEIN CATABOLIC PROCESS | 7 | 274 | 0.0002379 | 0.002137 |
519 | REGULATION OF ENDOTHELIAL CELL DIFFERENTIATION | 3 | 27 | 0.0002384 | 0.002137 |
520 | CELL CYCLE CHECKPOINT | 6 | 194 | 0.0002442 | 0.002185 |
521 | REGULATION OF CELL JUNCTION ASSEMBLY | 4 | 68 | 0.0002506 | 0.002238 |
522 | EAR DEVELOPMENT | 6 | 195 | 0.000251 | 0.002238 |
523 | NEURON DEVELOPMENT | 11 | 687 | 0.0002564 | 0.002281 |
524 | POSITIVE REGULATION OF SECRETION | 8 | 370 | 0.0002634 | 0.002339 |
525 | G PROTEIN COUPLED RECEPTOR SIGNALING PATHWAY | 15 | 1193 | 0.0002649 | 0.002348 |
526 | NEGATIVE REGULATION OF DENDRITE DEVELOPMENT | 3 | 28 | 0.0002661 | 0.002354 |
527 | NEURAL PRECURSOR CELL PROLIFERATION | 4 | 70 | 0.0002802 | 0.002465 |
528 | MUSCLE ORGAN MORPHOGENESIS | 4 | 70 | 0.0002802 | 0.002465 |
529 | REGULATION OF MEMBRANE PERMEABILITY | 4 | 70 | 0.0002802 | 0.002465 |
530 | HOMEOSTATIC PROCESS | 16 | 1337 | 0.000282 | 0.00247 |
531 | REGULATION OF ESTABLISHMENT OF PROTEIN LOCALIZATION TO MITOCHONDRION | 5 | 128 | 0.0002824 | 0.00247 |
532 | MUSCLE CELL DEVELOPMENT | 5 | 128 | 0.0002824 | 0.00247 |
533 | REGULATION OF REPRODUCTIVE PROCESS | 5 | 129 | 0.0002928 | 0.002551 |
534 | CELL JUNCTION ASSEMBLY | 5 | 129 | 0.0002928 | 0.002551 |
535 | POSITIVE REGULATION OF CELL ADHESION | 8 | 376 | 0.0002934 | 0.002552 |
536 | REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 3 | 29 | 0.0002958 | 0.002554 |
537 | POSITIVE REGULATION OF PROTEIN INSERTION INTO MITOCHONDRIAL MEMBRANE INVOLVED IN APOPTOTIC SIGNALING PATHWAY | 3 | 29 | 0.0002958 | 0.002554 |
538 | STEM CELL DIVISION | 3 | 29 | 0.0002958 | 0.002554 |
539 | REGULATION OF HEART MORPHOGENESIS | 3 | 29 | 0.0002958 | 0.002554 |
540 | REGULATION OF SECRETION | 11 | 699 | 0.0002973 | 0.002562 |
541 | DEPHOSPHORYLATION | 7 | 286 | 0.0003085 | 0.002653 |
542 | ENDOTHELIAL CELL DIFFERENTIATION | 4 | 72 | 0.0003123 | 0.002681 |
543 | NEGATIVE REGULATION OF MAP KINASE ACTIVITY | 4 | 73 | 0.0003293 | 0.002796 |
544 | POSITIVE REGULATION OF PROTEIN BINDING | 4 | 73 | 0.0003293 | 0.002796 |
545 | ESTABLISHMENT OR MAINTENANCE OF EPITHELIAL CELL APICAL BASAL POLARITY | 3 | 30 | 0.0003276 | 0.002796 |
546 | NEGATIVE REGULATION OF MUSCLE CELL APOPTOTIC PROCESS | 3 | 30 | 0.0003276 | 0.002796 |
547 | APOPTOTIC SIGNALING PATHWAY | 7 | 289 | 0.0003285 | 0.002796 |
548 | RESPONSE TO X RAY | 3 | 30 | 0.0003276 | 0.002796 |
549 | REGULATION OF DENDRITE MORPHOGENESIS | 4 | 74 | 0.0003469 | 0.002935 |
550 | CELL CELL JUNCTION ASSEMBLY | 4 | 74 | 0.0003469 | 0.002935 |
551 | REGULATION OF PEPTIDE SECRETION | 6 | 209 | 0.0003638 | 0.003072 |
552 | REGULATION OF PROTEIN SECRETION | 8 | 389 | 0.0003682 | 0.003104 |
553 | RESPONSE TO STEROID HORMONE | 9 | 497 | 0.0003991 | 0.003358 |
554 | REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 6 | 213 | 0.0004024 | 0.00338 |
555 | MODULATION OF SYNAPTIC TRANSMISSION | 7 | 301 | 0.0004195 | 0.003517 |
556 | REGULATION OF SYNAPTIC PLASTICITY | 5 | 140 | 0.0004267 | 0.003571 |
557 | POSITIVE REGULATION OF CELL PROJECTION ORGANIZATION | 7 | 303 | 0.0004364 | 0.003645 |
558 | REGULATION OF MITOCHONDRION ORGANIZATION | 6 | 218 | 0.0004551 | 0.003781 |
559 | RESPONSE TO ESTROGEN | 6 | 218 | 0.0004551 | 0.003781 |
560 | CELLULAR RESPONSE TO STEROID HORMONE STIMULUS | 6 | 218 | 0.0004551 | 0.003781 |
561 | RESPONSE TO NITROGEN COMPOUND | 12 | 859 | 0.0004589 | 0.003806 |
562 | REGULATION OF SYSTEM PROCESS | 9 | 507 | 0.0004609 | 0.003816 |
563 | CELLULAR RESPONSE TO MECHANICAL STIMULUS | 4 | 80 | 0.0004671 | 0.003861 |
564 | REGULATION OF PROTEIN DEACETYLATION | 3 | 34 | 0.0004766 | 0.003918 |
565 | ORGAN FORMATION | 3 | 34 | 0.0004766 | 0.003918 |
566 | NEURAL TUBE PATTERNING | 3 | 34 | 0.0004766 | 0.003918 |
567 | POSITIVE REGULATION OF IMMUNE SYSTEM PROCESS | 12 | 867 | 0.0004984 | 0.00409 |
568 | SYNAPSE ORGANIZATION | 5 | 145 | 0.0005009 | 0.004096 |
569 | NEGATIVE REGULATION OF MAPK CASCADE | 5 | 145 | 0.0005009 | 0.004096 |
570 | REGULATION OF NEURON PROJECTION DEVELOPMENT | 8 | 408 | 0.000505 | 0.004122 |
571 | JNK CASCADE | 4 | 82 | 0.0005131 | 0.004181 |
572 | RESPONSE TO ESTRADIOL | 5 | 146 | 0.0005169 | 0.004197 |
573 | NEGATIVE REGULATION OF CELL CYCLE PHASE TRANSITION | 5 | 146 | 0.0005169 | 0.004197 |
574 | CHEMICAL HOMEOSTASIS | 12 | 874 | 0.0005354 | 0.00434 |
575 | POSITIVE REGULATION OF CELL GROWTH | 5 | 148 | 0.0005499 | 0.00445 |
576 | CHROMOSOME ORGANIZATION | 13 | 1009 | 0.0005644 | 0.004517 |
577 | POSITIVE REGULATION OF MUSCLE CELL DIFFERENTIATION | 4 | 84 | 0.0005621 | 0.004517 |
578 | NEGATIVE REGULATION OF DEVELOPMENTAL GROWTH | 4 | 84 | 0.0005621 | 0.004517 |
579 | NEGATIVE REGULATION OF MUSCLE ORGAN DEVELOPMENT | 3 | 36 | 0.000565 | 0.004517 |
580 | NEGATIVE REGULATION OF MUSCLE TISSUE DEVELOPMENT | 3 | 36 | 0.000565 | 0.004517 |
581 | POSITIVE REGULATION OF OSSIFICATION | 4 | 84 | 0.0005621 | 0.004517 |
582 | HEAD MORPHOGENESIS | 3 | 36 | 0.000565 | 0.004517 |
583 | REGULATION OF STRIATED MUSCLE CELL DIFFERENTIATION | 4 | 85 | 0.0005879 | 0.004684 |
584 | REGULATION OF CHROMOSOME SEGREGATION | 4 | 85 | 0.0005879 | 0.004684 |
585 | POSITIVE REGULATION OF LOCOMOTION | 8 | 420 | 0.0006107 | 0.00485 |
586 | NEGATIVE REGULATION OF EPITHELIAL CELL DIFFERENTIATION | 3 | 37 | 0.0006129 | 0.00485 |
587 | ESTABLISHMENT OR MAINTENANCE OF APICAL BASAL CELL POLARITY | 3 | 37 | 0.0006129 | 0.00485 |
588 | ESTABLISHMENT OR MAINTENANCE OF BIPOLAR CELL POLARITY | 3 | 37 | 0.0006129 | 0.00485 |
589 | REGULATION OF CHROMATIN ORGANIZATION | 5 | 152 | 0.0006207 | 0.004903 |
590 | POSITIVE REGULATION OF NEURON PROJECTION DEVELOPMENT | 6 | 232 | 0.0006315 | 0.00498 |
591 | NEGATIVE REGULATION OF CYSTEINE TYPE ENDOPEPTIDASE ACTIVITY | 4 | 88 | 0.0006701 | 0.005276 |
592 | ACTIVATION OF IMMUNE RESPONSE | 8 | 427 | 0.0006803 | 0.005347 |
593 | POSITIVE REGULATION OF DEVELOPMENTAL GROWTH | 5 | 156 | 0.0006981 | 0.005468 |
594 | CELLULAR RESPONSE TO INORGANIC SUBSTANCE | 5 | 156 | 0.0006981 | 0.005468 |
595 | EPITHELIAL CELL PROLIFERATION | 4 | 89 | 0.0006993 | 0.005469 |
596 | CELL PROJECTION ORGANIZATION | 12 | 902 | 0.000707 | 0.005519 |
597 | NEGATIVE REGULATION OF PROTEOLYSIS | 7 | 329 | 0.0007108 | 0.00554 |
598 | REGULATION OF CELL MATRIX ADHESION | 4 | 90 | 0.0007293 | 0.005675 |
599 | APICAL JUNCTION ASSEMBLY | 3 | 40 | 0.0007718 | 0.005975 |
600 | REGULATION OF MEIOTIC CELL CYCLE | 3 | 40 | 0.0007718 | 0.005975 |
601 | POSITIVE REGULATION OF CELL MATRIX ADHESION | 3 | 40 | 0.0007718 | 0.005975 |
602 | NEGATIVE REGULATION OF INTRACELLULAR SIGNAL TRANSDUCTION | 8 | 437 | 0.0007907 | 0.006111 |
603 | MITOCHONDRIAL MEMBRANE ORGANIZATION | 4 | 92 | 0.0007921 | 0.006112 |
604 | REGULATION OF MICROTUBULE BASED PROCESS | 6 | 243 | 0.0008041 | 0.006194 |
605 | NEGATIVE REGULATION OF STRESS ACTIVATED MAPK CASCADE | 3 | 41 | 0.00083 | 0.006363 |
606 | NEGATIVE REGULATION OF STRESS ACTIVATED PROTEIN KINASE SIGNALING CASCADE | 3 | 41 | 0.00083 | 0.006363 |
607 | PROSTATE GLAND DEVELOPMENT | 3 | 41 | 0.00083 | 0.006363 |
608 | RESPONSE TO EXTRACELLULAR STIMULUS | 8 | 441 | 0.0008386 | 0.006418 |
609 | POSITIVE REGULATION OF INNATE IMMUNE RESPONSE | 6 | 246 | 0.0008569 | 0.006547 |
610 | SYSTEM PROCESS | 18 | 1785 | 0.0008848 | 0.006749 |
611 | TRANSFORMING GROWTH FACTOR BETA RECEPTOR SIGNALING PATHWAY | 4 | 95 | 0.0008933 | 0.006803 |
612 | REGULATION OF CELL PROJECTION ORGANIZATION | 9 | 558 | 0.0009124 | 0.006937 |
613 | COVALENT CHROMATIN MODIFICATION | 7 | 345 | 0.0009382 | 0.007121 |
614 | OSSIFICATION | 6 | 251 | 0.0009509 | 0.007206 |
615 | PROTEOLYSIS | 14 | 1208 | 0.0009675 | 0.00732 |
616 | REGULATION OF AXONOGENESIS | 5 | 168 | 0.000974 | 0.007357 |
617 | MEMORY | 4 | 98 | 0.001003 | 0.007542 |
618 | POSITIVE REGULATION OF PROTEASOMAL PROTEIN CATABOLIC PROCESS | 4 | 98 | 0.001003 | 0.007542 |
619 | RESPONSE TO VITAMIN | 4 | 98 | 0.001003 | 0.007542 |
620 | BODY MORPHOGENESIS | 3 | 44 | 0.001021 | 0.00764 |
621 | BRANCHING INVOLVED IN URETERIC BUD MORPHOGENESIS | 3 | 44 | 0.001021 | 0.00764 |
622 | NEGATIVE REGULATION OF MYELOID LEUKOCYTE DIFFERENTIATION | 3 | 44 | 0.001021 | 0.00764 |
623 | NEGATIVE REGULATION OF TRANSFERASE ACTIVITY | 7 | 351 | 0.001037 | 0.007745 |
624 | POSITIVE REGULATION OF CELL SUBSTRATE ADHESION | 4 | 99 | 0.001042 | 0.00777 |
625 | PRIMITIVE STREAK FORMATION | 2 | 11 | 0.001073 | 0.007961 |
626 | ENDOCARDIUM DEVELOPMENT | 2 | 11 | 0.001073 | 0.007961 |
627 | ENDOTHELIAL TUBE MORPHOGENESIS | 2 | 11 | 0.001073 | 0.007961 |
628 | LUNG MORPHOGENESIS | 3 | 45 | 0.001091 | 0.008068 |
629 | REGULATION OF EPIDERMAL CELL DIFFERENTIATION | 3 | 45 | 0.001091 | 0.008068 |
630 | CELL DIVISION | 8 | 460 | 0.0011 | 0.008122 |
631 | STRIATED MUSCLE CELL DIFFERENTIATION | 5 | 173 | 0.00111 | 0.008186 |
632 | REGULATION OF CHONDROCYTE DIFFERENTIATION | 3 | 46 | 0.001163 | 0.008562 |
633 | POSITIVE REGULATION OF CYTOSKELETON ORGANIZATION | 5 | 175 | 0.001168 | 0.008588 |
634 | PROTEIN CATABOLIC PROCESS | 9 | 579 | 0.001181 | 0.008668 |
635 | POSITIVE REGULATION BY HOST OF VIRAL TRANSCRIPTION | 2 | 12 | 0.001284 | 0.009274 |
636 | ANTERIOR POSTERIOR AXIS SPECIFICATION EMBRYO | 2 | 12 | 0.001284 | 0.009274 |
637 | CARTILAGE MORPHOGENESIS | 2 | 12 | 0.001284 | 0.009274 |
638 | REGULATION OF ENDOTHELIAL CELL DEVELOPMENT | 2 | 12 | 0.001284 | 0.009274 |
639 | ROSTROCAUDAL NEURAL TUBE PATTERNING | 2 | 12 | 0.001284 | 0.009274 |
640 | HEART FORMATION | 2 | 12 | 0.001284 | 0.009274 |
641 | REGULATION OF ESTABLISHMENT OF ENDOTHELIAL BARRIER | 2 | 12 | 0.001284 | 0.009274 |
642 | TRIPARTITE REGIONAL SUBDIVISION | 2 | 12 | 0.001284 | 0.009274 |
643 | MAMMARY GLAND EPITHELIAL CELL PROLIFERATION | 2 | 12 | 0.001284 | 0.009274 |
644 | LENS FIBER CELL DEVELOPMENT | 2 | 12 | 0.001284 | 0.009274 |
645 | REGULATION OF CARDIAC MUSCLE TISSUE DEVELOPMENT | 3 | 48 | 0.001316 | 0.009468 |
646 | REGULATION OF MYOBLAST DIFFERENTIATION | 3 | 48 | 0.001316 | 0.009468 |
647 | POSITIVE REGULATION OF ACTIN FILAMENT BUNDLE ASSEMBLY | 3 | 48 | 0.001316 | 0.009468 |
648 | CELL MORPHOGENESIS INVOLVED IN NEURON DIFFERENTIATION | 7 | 368 | 0.001362 | 0.009778 |
649 | PEPTIDYL AMINO ACID MODIFICATION | 11 | 841 | 0.001369 | 0.009814 |
650 | RESPONSE TO KETONE | 5 | 182 | 0.00139 | 0.009951 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | WNT PROTEIN BINDING | 14 | 31 | 1.206e-25 | 5.602e-23 |
2 | WNT ACTIVATED RECEPTOR ACTIVITY | 13 | 22 | 6.04e-26 | 5.602e-23 |
3 | FRIZZLED BINDING | 14 | 36 | 1.696e-24 | 5.252e-22 |
4 | BETA CATENIN BINDING | 15 | 84 | 2.133e-20 | 4.954e-18 |
5 | ENZYME BINDING | 32 | 1737 | 1.358e-12 | 2.524e-10 |
6 | TRANSCRIPTION FACTOR BINDING | 19 | 524 | 1.645e-12 | 2.548e-10 |
7 | G PROTEIN COUPLED RECEPTOR BINDING | 14 | 259 | 9.882e-12 | 1.311e-09 |
8 | RECEPTOR BINDING | 27 | 1476 | 1.579e-10 | 1.834e-08 |
9 | SIGNAL TRANSDUCER ACTIVITY | 29 | 1731 | 2.158e-10 | 2.227e-08 |
10 | PROTEIN DOMAIN SPECIFIC BINDING | 18 | 624 | 2.877e-10 | 2.673e-08 |
11 | PROTEIN SERINE THREONINE KINASE ACTIVITY | 15 | 445 | 1.278e-09 | 1.08e-07 |
12 | PDZ DOMAIN BINDING | 8 | 90 | 7.024e-09 | 5.438e-07 |
13 | REGULATORY REGION NUCLEIC ACID BINDING | 18 | 818 | 2.019e-08 | 1.443e-06 |
14 | PROTEIN KINASE ACTIVITY | 16 | 640 | 2.39e-08 | 1.586e-06 |
15 | I SMAD BINDING | 4 | 11 | 1.235e-07 | 7.649e-06 |
16 | GAMMA CATENIN BINDING | 4 | 12 | 1.846e-07 | 1.072e-05 |
17 | ARMADILLO REPEAT DOMAIN BINDING | 4 | 13 | 2.658e-07 | 1.452e-05 |
18 | MAP KINASE ACTIVITY | 4 | 14 | 3.708e-07 | 1.914e-05 |
19 | RNA POLYMERASE II TRANSCRIPTION FACTOR BINDING | 7 | 104 | 4.396e-07 | 2.15e-05 |
20 | KINASE BINDING | 14 | 606 | 5.134e-07 | 2.385e-05 |
21 | SMAD BINDING | 6 | 72 | 8.634e-07 | 3.819e-05 |
22 | KINASE ACTIVITY | 16 | 842 | 9.786e-07 | 4.132e-05 |
23 | RHO GTPASE BINDING | 6 | 78 | 1.389e-06 | 5.61e-05 |
24 | CALMODULIN BINDING | 8 | 179 | 1.46e-06 | 5.653e-05 |
25 | UBIQUITIN LIKE PROTEIN LIGASE BINDING | 9 | 264 | 2.952e-06 | 0.0001097 |
26 | RNA POLYMERASE II TRANSCRIPTION FACTOR ACTIVITY SEQUENCE SPECIFIC DNA BINDING | 13 | 629 | 4.632e-06 | 0.0001655 |
27 | CORE PROMOTER PROXIMAL REGION DNA BINDING | 10 | 371 | 6.546e-06 | 0.0002252 |
28 | MOLECULAR FUNCTION REGULATOR | 19 | 1353 | 7.435e-06 | 0.0002467 |
29 | TRANSFERASE ACTIVITY TRANSFERRING PHOSPHORUS CONTAINING GROUPS | 16 | 992 | 8.036e-06 | 0.0002574 |
30 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II TRANSCRIPTION REGULATORY REGION SEQUENCE SPECIFIC BINDING | 9 | 315 | 1.228e-05 | 0.0003803 |
31 | NUCLEIC ACID BINDING TRANSCRIPTION FACTOR ACTIVITY | 17 | 1199 | 2.163e-05 | 0.0006482 |
32 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR BINDING | 3 | 15 | 3.856e-05 | 0.001119 |
33 | PHOSPHORIC ESTER HYDROLASE ACTIVITY | 9 | 368 | 4.17e-05 | 0.001174 |
34 | PROTEIN DIMERIZATION ACTIVITY | 16 | 1149 | 4.864e-05 | 0.00128 |
35 | RECEPTOR AGONIST ACTIVITY | 3 | 16 | 4.73e-05 | 0.00128 |
36 | RECEPTOR REGULATOR ACTIVITY | 4 | 45 | 4.961e-05 | 0.00128 |
37 | SEQUENCE SPECIFIC DNA BINDING | 15 | 1037 | 5.634e-05 | 0.001415 |
38 | TRANSCRIPTION FACTOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 8 | 328 | 0.0001159 | 0.002834 |
39 | ACTIVATING TRANSCRIPTION FACTOR BINDING | 4 | 57 | 0.0001262 | 0.00295 |
40 | RECEPTOR SIGNALING PROTEIN ACTIVITY | 6 | 172 | 0.000127 | 0.00295 |
41 | DRUG BINDING | 5 | 109 | 0.0001333 | 0.003021 |
42 | R SMAD BINDING | 3 | 23 | 0.0001462 | 0.003226 |
43 | CHROMATIN BINDING | 9 | 435 | 0.0001493 | 0.003226 |
44 | PHOSPHOPROTEIN PHOSPHATASE ACTIVITY | 6 | 178 | 0.0001532 | 0.003234 |
45 | DOUBLE STRANDED DNA BINDING | 12 | 764 | 0.0001577 | 0.003256 |
46 | MITOGEN ACTIVATED PROTEIN KINASE BINDING | 3 | 24 | 0.0001666 | 0.003364 |
47 | PROTEIN SERINE THREONINE PHOSPHATASE ACTIVITY | 4 | 64 | 0.0001982 | 0.003918 |
48 | P53 BINDING | 4 | 67 | 0.0002367 | 0.004581 |
49 | CALMODULIN DEPENDENT PROTEIN KINASE ACTIVITY | 3 | 28 | 0.0002661 | 0.004944 |
50 | CADHERIN BINDING | 3 | 28 | 0.0002661 | 0.004944 |
51 | TRANSCRIPTION FACTOR ACTIVITY PROTEIN BINDING | 10 | 588 | 0.0003094 | 0.005637 |
52 | NF KAPPAB BINDING | 3 | 30 | 0.0003276 | 0.005853 |
53 | PHOSPHOLIPASE C ACTIVITY | 3 | 31 | 0.0003616 | 0.006337 |
54 | TRANSCRIPTION COACTIVATOR ACTIVITY | 7 | 296 | 0.0003794 | 0.006527 |
55 | RECEPTOR ACTIVATOR ACTIVITY | 3 | 32 | 0.0003977 | 0.006717 |
56 | STEROID HORMONE RECEPTOR BINDING | 4 | 81 | 0.0004897 | 0.008124 |
57 | G PROTEIN COUPLED RECEPTOR ACTIVITY | 12 | 879 | 0.0005631 | 0.008897 |
58 | TRANSCRIPTIONAL ACTIVATOR ACTIVITY RNA POLYMERASE II CORE PROMOTER PROXIMAL REGION SEQUENCE SPECIFIC BINDING | 6 | 226 | 0.0005504 | 0.008897 |
59 | RNA POLYMERASE II ACTIVATING TRANSCRIPTION FACTOR BINDING | 3 | 36 | 0.000565 | 0.008897 |
Num | GO | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|
1 | BETA CATENIN DESTRUCTION COMPLEX | 8 | 14 | 3.592e-16 | 2.098e-13 |
2 | WNT SIGNALOSOME | 7 | 11 | 9.578e-15 | 2.797e-12 |
3 | PHOSPHATASE COMPLEX | 7 | 48 | 1.868e-09 | 3.636e-07 |
4 | TRANSCRIPTION FACTOR COMPLEX | 12 | 298 | 9.334e-09 | 1.363e-06 |
5 | ENDOCYTIC VESICLE MEMBRANE | 8 | 152 | 4.234e-07 | 4.946e-05 |
6 | NUCLEAR CHROMATIN | 10 | 291 | 7.473e-07 | 7.274e-05 |
7 | CHROMOSOME | 16 | 880 | 1.741e-06 | 0.0001141 |
8 | NUCLEAR TRANSCRIPTION FACTOR COMPLEX | 7 | 127 | 1.701e-06 | 0.0001141 |
9 | PROTEIN PHOSPHATASE TYPE 2A COMPLEX | 4 | 20 | 1.758e-06 | 0.0001141 |
10 | ENDOCYTIC VESICLE | 9 | 256 | 2.294e-06 | 0.000134 |
11 | EXTRACELLULAR MATRIX | 11 | 426 | 3.306e-06 | 0.0001755 |
12 | CHROMATIN | 11 | 441 | 4.6e-06 | 0.0002066 |
13 | PROTEINACEOUS EXTRACELLULAR MATRIX | 10 | 356 | 4.553e-06 | 0.0002066 |
14 | CELL SURFACE | 14 | 757 | 6.899e-06 | 0.0002878 |
15 | CATALYTIC COMPLEX | 15 | 1038 | 5.696e-05 | 0.002218 |
16 | CENTROSOME | 10 | 487 | 6.696e-05 | 0.002444 |
17 | LATERAL PLASMA MEMBRANE | 4 | 50 | 7.538e-05 | 0.002589 |
18 | RNA POLYMERASE II TRANSCRIPTION FACTOR COMPLEX | 5 | 101 | 9.299e-05 | 0.003017 |
19 | MICROTUBULE ORGANIZING CENTER | 11 | 623 | 0.0001097 | 0.003371 |
20 | NUCLEAR CHROMOSOME | 10 | 523 | 0.0001205 | 0.003519 |
21 | LAMELLIPODIUM | 6 | 172 | 0.000127 | 0.003533 |
22 | INTRACELLULAR VESICLE | 16 | 1259 | 0.0001423 | 0.003613 |
23 | SYNAPSE | 12 | 754 | 0.0001395 | 0.003613 |
24 | CYTOSKELETAL PART | 17 | 1436 | 0.0002011 | 0.004894 |
25 | CLATHRIN COATED ENDOCYTIC VESICLE | 4 | 65 | 0.0002105 | 0.004917 |
26 | MICROTUBULE CYTOSKELETON | 14 | 1068 | 0.000285 | 0.006164 |
27 | APICAL JUNCTION COMPLEX | 5 | 128 | 0.0002824 | 0.006164 |
28 | CELL CELL JUNCTION | 8 | 383 | 0.000332 | 0.006924 |
29 | CYTOSKELETON | 20 | 1967 | 0.0003889 | 0.007831 |
30 | VESICLE MEMBRANE | 9 | 512 | 0.0004947 | 0.009631 |
Num | Pathway | Pathview | Overlap | Size | P Value | Adj. P Value |
---|---|---|---|---|---|---|
1 | hsa04310_Wnt_signaling_pathway | 90 | 151 | 1.678e-206 | 3.02e-204 | |
2 | hsa04916_Melanogenesis | 35 | 101 | 4.924e-59 | 4.432e-57 | |
3 | hsa04390_Hippo_signaling_pathway | 34 | 154 | 1.409e-49 | 8.456e-48 | |
4 | hsa04720_Long.term_potentiation | 15 | 70 | 1.092e-21 | 4.913e-20 | |
5 | hsa04520_Adherens_junction | 13 | 73 | 8.724e-18 | 3.141e-16 | |
6 | hsa04340_Hedgehog_signaling_pathway | 12 | 56 | 1.531e-17 | 4.593e-16 | |
7 | hsa04114_Oocyte_meiosis | 13 | 114 | 3.782e-15 | 9.726e-14 | |
8 | hsa04360_Axon_guidance | 13 | 130 | 2.156e-14 | 4.85e-13 | |
9 | hsa04912_GnRH_signaling_pathway | 12 | 101 | 2.778e-14 | 5.555e-13 | |
10 | hsa04662_B_cell_receptor_signaling_pathway | 11 | 75 | 3.157e-14 | 5.682e-13 | |
11 | hsa04370_VEGF_signaling_pathway | 11 | 76 | 3.678e-14 | 6.018e-13 | |
12 | hsa04010_MAPK_signaling_pathway | 15 | 268 | 1.017e-12 | 1.526e-11 | |
13 | hsa04020_Calcium_signaling_pathway | 13 | 177 | 1.191e-12 | 1.649e-11 | |
14 | hsa04660_T_cell_receptor_signaling_pathway | 11 | 108 | 1.972e-12 | 2.536e-11 | |
15 | hsa04350_TGF.beta_signaling_pathway | 10 | 85 | 4.836e-12 | 5.804e-11 | |
16 | hsa04012_ErbB_signaling_pathway | 10 | 87 | 6.139e-12 | 6.906e-11 | |
17 | hsa04650_Natural_killer_cell_mediated_cytotoxicity | 11 | 136 | 2.514e-11 | 2.662e-10 | |
18 | hsa04971_Gastric_acid_secretion | 9 | 74 | 4.371e-11 | 4.371e-10 | |
19 | hsa04510_Focal_adhesion | 12 | 200 | 9.944e-11 | 9.421e-10 | |
20 | hsa04270_Vascular_smooth_muscle_contraction | 9 | 116 | 2.586e-09 | 2.327e-08 | |
21 | hsa04722_Neurotrophin_signaling_pathway | 9 | 127 | 5.774e-09 | 4.949e-08 | |
22 | hsa04110_Cell_cycle | 8 | 128 | 1.128e-07 | 8.825e-07 | |
23 | hsa04380_Osteoclast_differentiation | 8 | 128 | 1.128e-07 | 8.825e-07 | |
24 | hsa04062_Chemokine_signaling_pathway | 9 | 189 | 1.815e-07 | 1.361e-06 | |
25 | hsa04730_Long.term_depression | 6 | 70 | 7.298e-07 | 5.254e-06 | |
26 | hsa04664_Fc_epsilon_RI_signaling_pathway | 6 | 79 | 1.498e-06 | 1.037e-05 | |
27 | hsa04330_Notch_signaling_pathway | 5 | 47 | 2.179e-06 | 1.453e-05 | |
28 | hsa04970_Salivary_secretion | 6 | 89 | 3.021e-06 | 1.942e-05 | |
29 | hsa04540_Gap_junction | 6 | 90 | 3.225e-06 | 2.002e-05 | |
30 | hsa04972_Pancreatic_secretion | 6 | 101 | 6.309e-06 | 3.786e-05 | |
31 | hsa04014_Ras_signaling_pathway | 8 | 236 | 1.126e-05 | 6.537e-05 | |
32 | hsa04670_Leukocyte_transendothelial_migration | 6 | 117 | 1.47e-05 | 8.269e-05 | |
33 | hsa04070_Phosphatidylinositol_signaling_system | 5 | 78 | 2.688e-05 | 0.0001466 | |
34 | hsa04530_Tight_junction | 6 | 133 | 3.043e-05 | 0.0001611 | |
35 | hsa04210_Apoptosis | 5 | 89 | 5.084e-05 | 0.0002615 | |
36 | hsa04910_Insulin_signaling_pathway | 5 | 138 | 0.0003994 | 0.001997 | |
37 | hsa04810_Regulation_of_actin_cytoskeleton | 6 | 214 | 0.0004126 | 0.002007 | |
38 | hsa04914_Progesterone.mediated_oocyte_maturation | 4 | 87 | 0.0006419 | 0.00304 | |
39 | hsa04151_PI3K_AKT_signaling_pathway | 7 | 351 | 0.001037 | 0.004786 | |
40 | hsa00562_Inositol_phosphate_metabolism | 3 | 57 | 0.002163 | 0.009734 | |
41 | hsa04621_NOD.like_receptor_signaling_pathway | 3 | 59 | 0.002388 | 0.01048 | |
42 | hsa04920_Adipocytokine_signaling_pathway | 3 | 68 | 0.003576 | 0.01532 | |
43 | hsa04622_RIG.I.like_receptor_signaling_pathway | 3 | 71 | 0.004038 | 0.01691 | |
44 | hsa04710_Circadian_rhythm_._mammal | 2 | 23 | 0.004764 | 0.01949 | |
45 | hsa04630_Jak.STAT_signaling_pathway | 4 | 155 | 0.005292 | 0.02117 | |
46 | hsa03015_mRNA_surveillance_pathway | 3 | 83 | 0.006246 | 0.02444 | |
47 | hsa04141_Protein_processing_in_endoplasmic_reticulum | 4 | 168 | 0.007011 | 0.02685 | |
48 | hsa04620_Toll.like_receptor_signaling_pathway | 3 | 102 | 0.01098 | 0.04118 | |
49 | hsa04960_Aldosterone.regulated_sodium_reabsorption | 2 | 42 | 0.01534 | 0.05636 | |
50 | hsa04973_Carbohydrate_digestion_and_absorption | 2 | 44 | 0.01676 | 0.06033 | |
51 | hsa04742_Taste_transduction | 2 | 52 | 0.02295 | 0.08102 | |
52 | hsa04120_Ubiquitin_mediated_proteolysis | 3 | 139 | 0.02489 | 0.08614 | |
53 | hsa04115_p53_signaling_pathway | 2 | 69 | 0.03867 | 0.1313 | |
54 | hsa04666_Fc_gamma_R.mediated_phagocytosis | 2 | 95 | 0.06833 | 0.2278 | |
55 | hsa04740_Olfactory_transduction | 4 | 388 | 0.09784 | 0.3202 | |
56 | hsa04144_Endocytosis | 2 | 203 | 0.2322 | 0.7333 |
Num | lncRNA | miRNAs | miRNAs count | Gene | Sponge regulatory network | lncRNA log2FC | lncRNA pvalue | Gene log2FC | Gene pvalue | lncRNA-gene Pearson correlation |
---|---|---|---|---|---|---|---|---|---|---|
1 | EMX2OS |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-130b-5p;hsa-miR-146a-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-18b-5p;hsa-miR-194-5p;hsa-miR-197-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-221-5p;hsa-miR-26a-1-3p;hsa-miR-26a-2-3p;hsa-miR-27a-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-33a-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-374a-3p;hsa-miR-421;hsa-miR-484;hsa-miR-576-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-624-5p;hsa-miR-629-3p;hsa-miR-7-1-3p | 38 | PRICKLE2 | Sponge network | 1.057 | 0.31716 | 0.551 | 0.42536 | 0.586 |
2 | CECR7 |
hsa-miR-141-5p;hsa-miR-148a-5p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-194-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-24-3p;hsa-miR-26b-5p;hsa-miR-29a-5p;hsa-miR-29b-1-5p;hsa-miR-30b-5p;hsa-miR-30c-5p;hsa-miR-30d-5p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-361-5p;hsa-miR-429;hsa-miR-491-5p;hsa-miR-502-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-7-1-3p | 24 | PRKCB | Sponge network | 0.551 | 0.56177 | -0.289 | 0.6299 | 0.583 |
3 | EMX2OS |
hsa-miR-144-3p;hsa-miR-146a-5p;hsa-miR-16-1-3p;hsa-miR-182-5p;hsa-miR-192-3p;hsa-miR-19b-1-5p;hsa-miR-26b-3p;hsa-miR-27a-3p;hsa-miR-29a-5p;hsa-miR-30d-3p;hsa-miR-335-5p;hsa-miR-33a-3p;hsa-miR-484;hsa-miR-576-5p;hsa-miR-625-5p;hsa-miR-7-1-3p;hsa-miR-940 | 17 | SFRP1 | Sponge network | 1.057 | 0.31716 | 0.459 | 0.49771 | 0.573 |
4 | EMX2OS |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-3p;hsa-miR-17-5p;hsa-miR-185-3p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-30b-3p;hsa-miR-30d-3p;hsa-miR-362-3p;hsa-miR-505-5p;hsa-miR-590-3p;hsa-miR-93-5p | 17 | TCF7L1 | Sponge network | 1.057 | 0.31716 | 0.403 | 0.47966 | 0.509 |
5 | CECR7 |
hsa-miR-130b-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-301a-3p;hsa-miR-429;hsa-miR-454-3p;hsa-miR-582-5p;hsa-miR-590-3p;hsa-miR-590-5p | 13 | MAPK10 | Sponge network | 0.551 | 0.56177 | 0.278 | 0.49976 | 0.504 |
6 | EMX2OS |
hsa-let-7a-3p;hsa-let-7d-5p;hsa-let-7f-1-3p;hsa-let-7g-3p;hsa-let-7g-5p;hsa-miR-106b-5p;hsa-miR-107;hsa-miR-10a-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-25-3p;hsa-miR-27a-3p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-32-5p;hsa-miR-324-3p;hsa-miR-33a-3p;hsa-miR-375;hsa-miR-424-5p;hsa-miR-452-5p;hsa-miR-454-3p;hsa-miR-484;hsa-miR-505-5p;hsa-miR-576-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-7-1-3p;hsa-miR-92a-3p;hsa-miR-940 | 41 | FZD4 | Sponge network | 1.057 | 0.31716 | 0.088 | 0.9264 | 0.501 |
7 | CECR7 |
hsa-miR-1275;hsa-miR-16-1-3p;hsa-miR-182-5p;hsa-miR-192-3p;hsa-miR-19b-1-5p;hsa-miR-26b-3p;hsa-miR-29a-5p;hsa-miR-335-5p;hsa-miR-33a-3p;hsa-miR-429;hsa-miR-625-5p;hsa-miR-7-1-3p | 12 | SFRP1 | Sponge network | 0.551 | 0.56177 | 0.459 | 0.49771 | 0.494 |
8 | CECR7 |
hsa-let-7a-3p;hsa-let-7d-5p;hsa-let-7f-1-3p;hsa-let-7g-3p;hsa-let-7g-5p;hsa-miR-106b-5p;hsa-miR-10a-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-3p;hsa-miR-17-5p;hsa-miR-185-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-24-3p;hsa-miR-25-3p;hsa-miR-301a-3p;hsa-miR-32-3p;hsa-miR-324-3p;hsa-miR-33a-3p;hsa-miR-361-5p;hsa-miR-375;hsa-miR-429;hsa-miR-454-3p;hsa-miR-505-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-7-1-3p | 36 | FZD4 | Sponge network | 0.551 | 0.56177 | 0.088 | 0.9264 | 0.486 |
9 | EMX2OS |
hsa-miR-146a-5p;hsa-miR-148b-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-335-5p;hsa-miR-577;hsa-miR-590-3p;hsa-miR-93-3p | 12 | FZD1 | Sponge network | 1.057 | 0.31716 | -0.051 | 0.95908 | 0.447 |
10 | EMX2OS |
hsa-miR-141-5p;hsa-miR-182-5p;hsa-miR-18a-5p;hsa-miR-1976;hsa-miR-19b-3p;hsa-miR-335-5p;hsa-miR-339-5p;hsa-miR-421;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-592 | 11 | DAAM2 | Sponge network | 1.057 | 0.31716 | 0.123 | 0.86624 | 0.445 |
11 | CECR7 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-130b-5p;hsa-miR-141-3p;hsa-miR-15b-3p;hsa-miR-17-5p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-362-3p;hsa-miR-429;hsa-miR-505-5p;hsa-miR-590-3p;hsa-miR-93-5p | 15 | TCF7L1 | Sponge network | 0.551 | 0.56177 | 0.403 | 0.47966 | 0.437 |
12 | CECR7 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-let-7f-2-3p;hsa-miR-130b-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-18a-5p;hsa-miR-18b-5p;hsa-miR-194-5p;hsa-miR-197-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-221-5p;hsa-miR-26a-1-3p;hsa-miR-26a-2-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-32-3p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-33a-3p;hsa-miR-33a-5p;hsa-miR-33b-5p;hsa-miR-361-5p;hsa-miR-362-5p;hsa-miR-429;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-590-5p;hsa-miR-629-3p;hsa-miR-7-1-3p | 36 | PRICKLE2 | Sponge network | 0.551 | 0.56177 | 0.551 | 0.42536 | 0.432 |
13 | MEG3 |
hsa-let-7f-5p;hsa-let-7g-5p;hsa-miR-106b-5p;hsa-miR-10a-5p;hsa-miR-130b-3p;hsa-miR-141-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-17-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-429;hsa-miR-576-5p;hsa-miR-590-5p;hsa-miR-7-1-3p | 19 | FZD4 | Sponge network | 0.433 | 0.33816 | 0.088 | 0.9264 | 0.417 |
14 | EMX2OS |
hsa-miR-130b-3p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-221-3p;hsa-miR-222-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-301a-3p;hsa-miR-30d-3p;hsa-miR-454-3p;hsa-miR-590-3p;hsa-miR-940 | 12 | MAPK10 | Sponge network | 1.057 | 0.31716 | 0.278 | 0.49976 | 0.408 |
15 | EMX2OS |
hsa-miR-141-5p;hsa-miR-148a-5p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-194-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-26b-5p;hsa-miR-27a-3p;hsa-miR-29a-5p;hsa-miR-29b-1-5p;hsa-miR-30d-3p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-452-3p;hsa-miR-484;hsa-miR-502-5p;hsa-miR-589-3p;hsa-miR-590-3p;hsa-miR-7-1-3p;hsa-miR-7-5p | 21 | PRKCB | Sponge network | 1.057 | 0.31716 | -0.289 | 0.6299 | 0.407 |
16 | MEG3 |
hsa-miR-106a-5p;hsa-miR-106b-5p;hsa-miR-141-3p;hsa-miR-15b-3p;hsa-miR-17-5p;hsa-miR-200a-3p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-20a-5p;hsa-miR-30b-3p;hsa-miR-30d-3p;hsa-miR-429;hsa-miR-93-5p | 13 | TCF7L1 | Sponge network | 0.433 | 0.33816 | 0.403 | 0.47966 | 0.398 |
17 | MIAT | hsa-miR-106b-5p;hsa-miR-10a-5p;hsa-miR-141-3p;hsa-miR-192-5p;hsa-miR-200c-3p;hsa-miR-24-3p;hsa-miR-301a-3p;hsa-miR-454-3p;hsa-miR-92a-3p;hsa-miR-98-5p | 10 | FZD4 | Sponge network | -0.118 | 0.86338 | 0.088 | 0.9264 | 0.397 |
18 | MEG3 |
hsa-miR-146a-5p;hsa-miR-148a-3p;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-194-5p;hsa-miR-221-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-429;hsa-miR-576-5p;hsa-miR-590-5p;hsa-miR-7-1-3p | 17 | PRICKLE2 | Sponge network | 0.433 | 0.33816 | 0.551 | 0.42536 | 0.389 |
19 | CECR7 |
hsa-miR-1275;hsa-miR-148b-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-335-5p;hsa-miR-590-3p | 10 | FZD1 | Sponge network | 0.551 | 0.56177 | -0.051 | 0.95908 | 0.388 |
20 | CECR7 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-148a-3p;hsa-miR-148b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-331-3p;hsa-miR-335-5p;hsa-miR-532-3p;hsa-miR-589-3p | 11 | WNT9A | Sponge network | 0.551 | 0.56177 | -0.153 | 0.81191 | 0.363 |
21 | EMX2OS |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-148a-3p;hsa-miR-148b-3p;hsa-miR-15a-5p;hsa-miR-15b-5p;hsa-miR-16-5p;hsa-miR-185-3p;hsa-miR-32-5p;hsa-miR-331-3p;hsa-miR-335-5p;hsa-miR-424-5p;hsa-miR-532-3p;hsa-miR-589-3p | 14 | WNT9A | Sponge network | 1.057 | 0.31716 | -0.153 | 0.81191 | 0.357 |
22 | MEG3 |
hsa-miR-146a-5p;hsa-miR-182-5p;hsa-miR-192-3p;hsa-miR-30d-3p;hsa-miR-335-5p;hsa-miR-429;hsa-miR-576-5p;hsa-miR-625-5p;hsa-miR-7-1-3p;hsa-miR-96-5p | 10 | SFRP1 | Sponge network | 0.433 | 0.33816 | 0.459 | 0.49771 | 0.357 |
23 | MEG3 |
hsa-miR-146a-5p;hsa-miR-148b-5p;hsa-miR-186-5p;hsa-miR-192-5p;hsa-miR-200a-5p;hsa-miR-200b-5p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-335-5p;hsa-miR-577 | 10 | FZD1 | Sponge network | 0.433 | 0.33816 | -0.051 | 0.95908 | 0.335 |
24 | HCG11 |
hsa-miR-130b-5p;hsa-miR-146a-5p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-197-3p;hsa-miR-26a-1-3p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-590-3p;hsa-miR-629-3p;hsa-miR-7-1-3p | 14 | PRICKLE2 | Sponge network | 0.419 | 0.63279 | 0.551 | 0.42536 | 0.335 |
25 | ZNF883 |
hsa-let-7a-3p;hsa-let-7f-1-3p;hsa-miR-130b-5p;hsa-miR-146a-5p;hsa-miR-148a-3p;hsa-miR-148a-5p;hsa-miR-148b-3p;hsa-miR-15b-3p;hsa-miR-16-2-3p;hsa-miR-182-5p;hsa-miR-186-5p;hsa-miR-194-5p;hsa-miR-19a-3p;hsa-miR-19b-3p;hsa-miR-26a-1-3p;hsa-miR-29a-3p;hsa-miR-29b-3p;hsa-miR-320c;hsa-miR-335-3p;hsa-miR-33a-3p;hsa-miR-576-5p;hsa-miR-590-5p | 22 | PRICKLE2 | Sponge network | 0.913 | 0.16772 | 0.551 | 0.42536 | 0.315 |
26 | MEG3 |
hsa-miR-141-5p;hsa-miR-16-2-3p;hsa-miR-186-5p;hsa-miR-194-5p;hsa-miR-200b-3p;hsa-miR-200c-3p;hsa-miR-26b-5p;hsa-miR-29b-1-5p;hsa-miR-30d-3p;hsa-miR-335-3p;hsa-miR-335-5p;hsa-miR-429;hsa-miR-590-5p;hsa-miR-7-1-3p | 14 | PRKCB | Sponge network | 0.433 | 0.33816 | -0.289 | 0.6299 | 0.266 |